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Abstract 
The hypothesis that age related muscle dysfunction is a result of diminished anabolic 
stimuli resulting in impaired amino acid uptake was tested as follows. Small muscle 
fibre bundles isolated from the extensor digitorum longus and the soleus of young, 
mature and elderly mice were used to investigated the effects of age and 
dihydrotestosterone (DHT) treatment on the expression and function of SNAT2 and 
LAT2. C2C12 muscle cells were cultured and tested for both SNAT2 and LAT2 function 
with DHT and various inhibitors.  
At all ages investigated, amino acid uptake was significantly higher in slow-twitch 
fibres than in the fast-twitch fibres. Ageing led to a decrease in amino acid uptake and 
protein synthesis in both fibre types. The decline was greater in the fast-twitch than in 
the slow-twitch fibres and was accompanied by a reduction in the expression of both 
SNAT 2 and LAT2 proteins. Mirroring the uptake results the decrease in SNAT 2 protein 
was greater in the fast-twitch fibres than in the slow-twitch fibres. The rends seen in 
SNAT2 uptake and expression were also seen with fluorescence imaging of muscle 
sections. Ageing had no effect on mRNA levels of LAT2, but has shown a significant 
reduction in SNAT2.  
Treating the muscle fibre bundles with physiological concentrations of DHT 
significantly increased amino acid uptake and SNAT2/LAT2 protein expression in the 
fast twitch fibres of all elderly group mice. There was a trend toward increased uptake 
and expression in response to DHT treatment in all groups. Chloroquine and flutamide 
treatment abolished the increased amino acid uptake induced by DHT treatment. 
Blocking SNAT2 in C2C12 cells with MeAIB resulted in decreased LAT2 response in 
starvation conditions, suggesting the role of these as transceptors. It is proposed that 
reduced anabolic stimuli in ageing leads to impairment of SNAT2/LAT2 recruitment 
leading to sarcopenia.  
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Chapter 1: Introduction 
1.1 Skeletal Muscle Physiology 
Skeletal muscle forms the bulk of body weight (around 40-50% of body mass in young 
adult males). It is also the main store of proteins in the body (Rooyackers and Nair, 
1997). In addition to its main physiological functions of postural support and control of 
movement, skeletal muscle is also vital to the maintenance of body shape, structure 
and composition.  
General muscle structure is shown on figure 1.1.  Skeletal muscle is composed of 
muscle fibres, further divided into sarcomeres, which are the smallest contractile units 
in skeletal muscle. These combine to form bundles called fascicles. The fascicles form 
the whole of the muscle, which is surrounded by a sheath called the epimysium on the 
outside of the muscle and the perimysium, which surrounds the fascicles on the inside. 
The muscle membrane underneath the epimysium is called the sarcolemma, which is 
composed of the plasma membrane of the muscle cell and a layer of polysaccharide. 
The muscle fibres fuses at the sarcolemma with the basement membrane with the 
help of transmembrane receptors on the sarcolemma. At lengthwise ends of the fibres, 
the distal ends of the sarcolemma fuse into tendons, which further attach to bones.  
Each muscle cell is composed of a tubular network of myofibrils. The myofibrils are 
further made up of repeating units called sarcomeres, each of which is composed of 
myofilaments. These myofilaments can be further categorised into thin and thick 
filaments, which interact and move over one another during contraction as described 
below (Boulpaep, 2012). 
Muscle tissue is specialised to perform the main function of generating force. Huxley et 
al. first described the sliding filament theory of muscle contraction in 1954 which has 
proven to be accurate (Huxley and Niedergerke, 1954). Contraction is initiated by the 
motor neuron and signalled by the neurotransmitter Acetylcholine, which is released 
at the neuromuscular junction and depolarises skeletal muscle cells. This in turn causes 
release of calcium ions from the skeletal cells sarcoplasmic reticulum. Calcium ions 
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bind to the protein troponin, resulting in a conformational change and the movement 
of tropomyosin. This exposes a myosin binding site on actin filaments.  
 
 
 
 
Figure 1.1 Illustration showing the structure of skeletal muscle. Notice that all muscle 
units are arranged in parallel, allowing for the generation of force through shortening 
of the sarcomeres. Myoblasts are progenitor cells which differentiate into functional 
myotubes (Randall et al., 1997). 
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Myosin binds to the active site and changes confirmation, which slides the filament 
forward. This is known as the power stroke of contraction, which is repeated over and 
over during a contraction event. The thin filaments in skeletal muscle slide over the 
thick filaments, thus generating tension in line with each sarcomere. The force 
generated pulls on the tendon, and if the force opposing the contraction is less than 
that being generated, movement results.  
Muscle fibre phenotype has more recently been considered as being closer to a 
continuum rather than rigidly characterised into two or three groups (Pette and 
Staron, 2000). However, the classical terminology is still a useful heuristic to group 
fibre types into three general categories based on their physical characteristics and 
isoforms of myosin expressed. This allows for easier classification of muscle groups.  
IIn humans, there have been four different muscle fibre types identified. In mice 
skeletal muscle theseare type 2B, 2D, 2A which contain the “fast” isoforms of myosin: 
MHC-2b, MHC-2d and MHC-2a respectively. Slow fibres contain MHC-1 and are 
donated as type 1 under this classification. In humans the 2D isoform is not present. 
This classification stems from the different isoforms speed of force production caused 
by the different isoform power stroke kinetics (Neunhauserer et al., 2011). This order 
can be expressed in decreasing kinetic action as: MHC-IIb>MHC-IId> MHC-IIa>>MHC-I. 
It is also important to note that hybrid fibres are abundant in mammals, which can 
express varying MHC isoforms, as well as post translational modifications that can alter 
kinetic function (Stephenson, 2001). 
Because of the complexity of fibre typing, it is simpler to look at the two extremes in 
muscle fibre types or a more classic view of fast vs slow. Type 1 oxidative are known as 
the classic “slow” fibres, and as their name suggest the metabolism in these fibres is 
centred around oxidative phosphorylation. This is the most efficient form of 
metabolism, yielding between 30 and 36 ATP per molecule of glucose (Korzeniewski, 
1998). An example of this is seen in aerobic exercise, as oxygen is necessary as an 
electron acceptor that drives the cycle. Type 2B are the classic fast twitch fibres, 
characterised by high force production and reliance on glycolysis, which generates 2 
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ATP from one glucose. Type 2A oxidative fibres fall in between the two classical 
extremes.  
 
As illustrated on the table below the two extremes of classical slow and fast muscle 
fibre types: 
Table 1: Muscle Fibre Types 
 SLOW OXIDATIVE FAST GLYCOLYTIC 
TWITCH SPEED SLOW FAST 
RESISTANCE TO FATIGUE HIGH LOW 
BLOOD SUPPLY HIGH LOW 
ATPase ACTIVITY LOW HIGH 
GLYCOGEN LOW HIGH 
TWITCH FORCE LOW HIGH 
COLOUR RED LIGHT PINK 
While skeletal muscle is vital to normal functioning and movement, there are 
numerous conditions that involve the atrophy of muscle. Skeletal muscle mass is 
maintained by a fine balance between protein synthesis and breakdown (Balagopal et 
al., 1997). Therefore, a decrease in skeletal muscle mass, such as that seen during 
ageing, must reflect an imbalance between these two processes, resulting in net 
nitrogen loss. Although several studies have previously reported a 30-40% reduction in 
mixed protein synthesis with age (Volpi et al., 2001, Toth et al., 2005), the direct 
anabolic effects of certain amino acids and endocrine factors are still intact in the 
elderly (Volpi et al., 1999). These findings have suggested that conditions of muscle 
wasting may be caused by failure in the transport of amino acids into and out of 
skeletal muscle fibre themselves.  
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1.2 Satellite Cells 
Another closely associated cell type called myosatellite cells lie between the 
sarcolemma and basement membrane of muscle fibres. Satellite cells are multipotent 
cells found on the mature skeletal muscle. Normally they are present in a quiescent 
state. Upon activation, they are able to proliferate as skeletal myoblasts, which have 
the ability to differentiate into functional skeletal muscle cells or back into satellite 
cells which acts to replenish the satellite cell pool of a fibre (Kadi et al., 2005, Birbrair 
and Delbono, 2015). Satellite cells are able to act as a source of nuclei to muscle fibres, 
which otherwise have no other mechanism to repair damaged nuclei. These cells have 
the capability to either form brand new myotubes or fuse with existing fibres (Kadi et 
al., 2004).  
Satellite cells are crucial for the repair and regeneration of damaged muscle. It has 
been found that elderly patients have a reduced pool of satellite cells which is a 
proposed factor in the onset and severity of age related muscular dysfunction 
(Joanisse et al., 2017). Their exact role in ageing has been a popular field of recent 
research.   
Satellite cells play a vital role in the regeneration and maintenance of healthy skeletal 
muscle fibres. Satellite cells respond to trauma and damage in skeletal muscle. (Seale 
et al., 2003) Because of their ability to replicate as well as differentiate into functional 
muscle fibres, the satellite cell pool as a whole does not become depleted. Fig 1.2 
Illustrates the typical response of skeletal muscle to injury and specifically the role of 
satellite cells in the regenerative process.  
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Figure 1.2 Diagram of muscle satellite cell mediated response to injury. (A) shows a single 
satellite cell in a muscle fibre with numerous nuclei. (B) In response to injury the satellite cells 
proliferate. (C) Most these proliferated cells differentiate into active myofibers. (D) A 
proportion of these cells become quiescent and return to their original location between the 
sarcolemma and basement membrane of the muscle fibres. Image from: (Morgan and 
Partridge, 2003). 
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However, it is not clear whether the satellite cell response changes with ageing. A 
higher rate of apoptosis in satellite cells has been discovered in elderly populations, 
most likely a result of impaired vascularisation (Wang et al., 2014). However, it is 
possible that this reduction is acting to retain proportionality of satellite cells to 
functional fibres, which also reduce in size with age. No proportional change has been 
found in the rat soleus in terms of satellite cell to fibre ratio (Brooks et al., 2009). It is 
proposed that it may be the function and response to stimuli that is impaired in 
satellite cells rather than their number (Hikida, 2011). Reduction in MAPK signalling, 
leading to impaired skeletal muscle cell self-renewal has been shown in ageing, 
possibly playing a smaller part in sarcopenic muscle dysfunction (Bernet et al., 2014). 
1.3 Amino Acid Transporters 
Amino acids enter and leave cells through highly specialised proteins known as amino 
acid transporters that are located on the cell membrane. The intracellular 
concentration of most amino acids in animal cells is normally higher than the 
extracellular amino acid concentration, meaning amino acids undergo active transport 
across plasma membranes against a gradient (Hyde et al., 2003). The 
sodium/potassium ATPase plays a vital role in many of the amino acid transporters. It 
is the most frequently expressed transporter, moving three molecules of sodium out of 
the cell in exchange for moving 2 molecules of potassium into the cell per one ATP. 
Many amino acid transporters, such as the system A transporters of the Slc38 family 
use the sodium gradient created to transfer amino acids into the cell via secondary 
active transport (Lingrel et al., 1994).  
These amino acid transporters play an important role in protein turnover by providing 
the building blocks necessary for protein synthesis (Volpi et al., 1999). A larger number 
of  different amino acid transporters are present in all mammalian cells (Wagner et al., 
2001). The focus of this thesis is particularly on two, the sodium-coupled neutral amino 
acid transporter, SNAT2 (Mackenzie and Erickson, 2004) and the sodium-independent 
L-type amino acid transporter LAT2. These two have been consistently found in 
significant quantities in skeletal muscle (Palacin et al., 1998).   
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1.3.1 SNAT2 
SNAT2 (Small Neutral Amino Acid Transporter) is a system A amino acid transporter 
first discovered in 1965 (Christensen et al., 1965) that belongs to the SLC38 gene family 
mentioned before. It mediates the sodium-coupled transport of small neutral amino 
acids such as glycineand alanine into muscle fibres. It transports one molecule of Na+ 
and one substrate amino acid into the cell. The substrate amino acid is preferentially a 
small neutral amino acid such as glycine. Larger neutral amino acids on the other hand 
are very poor substrates (Lopez et al., 2006). SNAT2 is widely expressed throughout 
the body, found in the brain, adipose tissue, liver, intestine, lung, kidney, and 
importantly, skeletal muscle (Mackenzie and Erickson, 2004). In fact, out of the Slc38 
gene family of transporters, it is the only one consistently found at measurable 
expression levels in skeletal muscle (Hyde et al., 2001). SNAT2 like the other members 
of its family of transporters shares the ability to transport a non metabolisable 
substrate known as methyl-aminoisobutyrate (MeAIB), a unique ability which also 
allows for the quantification of transport through these transporters.   
Structurally, SNAT2 is composed of 506 amino acids with a molecular weight of 56kDa. 
It spans the membrane with 11 transmembrane helices and contains a single 
disulphide  bridge (Chen et al., 2016). See figure 1.3.1 for a diagram of SNAT2 
structure. It has been discovered through hydropathy analysis that the transporter 
contains an intracellular N-terminus and also containing an extracellular C-terminus. 
This C-terminus does not play a role in amino acid substrate binding, but it does play a 
role in pH sensing and the transport of Na+ into the cell (Zhang et al., 2011). SNAT2 
shares a characteristic disulphide bride on its third extracellular loop with other 
members of the SNAT family of transporters. The exact function of this bond is 
unknown, but it is likely involved in translocation of the protein to the plasma 
membrane (Chen et al., 2016). 
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Figure 1.3.1 A model of SNAT2 showing general structure of the transporter. There are 11 
transmembrane helixes and a characteristic disulphide bond between Cys245 and Cys279.  
image from (Chen et al., 2016). 
 
 
Figure 1.3.2 Homology structural model comparing rat LAT2 with human (purple) LAT2 92% 
homogenous. Green sites represent possible PKA and PKC phosphorylation sites derived from 
Scan-Prosite software. Image from (Pochini et al., 2014). 
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Another characteristic feature of SNAT2, like all system A transporters is the 
phenomena of transinhibition. In other words, the accumulation of a system A 
substrate inside the cell acting to inhibit the transporter itself (Bracy et al., 1986). This 
is due to the accumulation of substrate inside the cytoplasm of the cell and can be 
achieved with only one amino acid. The dual role of some transporters to modulate 
their own expression, is likely achieved through initiation of signalling cascades such as 
MAPK (Pinilla et al., 2011).  This ability of transporters to act as transceptors and 
governing their own expression in response to changing nutrient availability has been 
documented in many cell types (Kriel et al., 2011). 
A well-documented phenomenon of SNAT2 is its adaptive regulation in response to 
amino acid deprivation (Hyde et al., 2001). Evidence suggests that the acute phase of 
this response, which happens during minutes rather than hours, is due to recruitment 
of SNAT2 from an internal pool localised in intracellular compartments (Hyde et al., 
2002). The exact mechanism involved in mediating the adaptive response of SNAT2 is 
not known. However, the PI3K and JNK pathways seem to be likely targets, as the 
inhibition of both respectively blunts the adaptive response (Hyde et al., 2007). ERK 
phosphorylation was also increased in amino acid deprivation. However, it is unclear if 
this pathway plays a role as its inhibition did not decrease the adaptive response.  
The addition of the amino acids L-Gln, L-Ala, L-Tyr as well as MeAIB also blunts the 
adaptive response (Hyde et al., 2007). The effectiveness of MeAIB in this case is 
notable, because as it is not metabolisable once within the cell, it suggests that the 
presence or movement of a substrate at SNAT2 is sufficient to blunt the adaptive 
response. This suggests that SNAT2 may in fact be a “transceptor”, playing a vital role 
in controlling amino acid uptake in response to changing extracellular amino acid 
levels.  
SNAT2 has shown to be sensitive to changes in pH. The activity of SNAT2 is reduced as 
the pH drops below physiological 7.4 (Munoz et al., 1992, Chaudhry et al., 2002, Baird 
et al., 2006). This sensitivity has shown to be mediated through the protonation of a 
histidine residue (Baird et al., 2006). This property can be used to validate uptake 
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studies and means that maintenance of a physiological pH is critical for accurate 
assays, which needs to be incorporated into the experimental design.  
There are three main triggers for the modulation of SNAT2 activity. These are osmotic 
shock, amino acid deprivation and hormonal stimulation such as insulin (Kashiwagi et 
al., 2009). ERK and JNK pathways are proposed to be active in upregulating de novo 
synthesis of SNAT2 via transcription along with the classical genomic pathway of AR 
binding. Both pathways appear to be in play during amino acid starvation, while only 
ERK is active in DHT induced acute upregulation of SNAT2 activity (Kashiwagi et al., 
2009, Hamdi and Mutungi, 2010). 
It has been shown that SNAT2 activity is directly controlled by hormones. Insulin has 
been shown to increase SNAT2 activity without increasing synthesis of new SNAT2. The 
proposed mechanism of this involves the exocytosis and endocytosis of SNAT2 from 
intracellular compartments (Hyde et al., 2002). In this way, SNAT2 activity is thought to 
be able to adapt quickly to meet the amino acid demands of the cell.  
Amino acid deprivation and osmotic shock have also been shown to upregulate SNAT2 
function, working through different pathways. It has been shown that AA starvation 
induced upregulation is blunted by PI3K and JNK inhibitors, while osmotic shock 
induced upregulation is blunted by mTOR inhibitors but not vice versa (Kashiwagi et 
al., 2009). Catechol amines have been shown to also upregulate System A activity in 
human liver parenchymal cells and rat hepatocyte, however this action seems to be 
mediated by transcription as it is completely inhibited by actinomycin D and 
cycloheximide (McGivan and Pastor-Anglada, 1994). The past work by Hamdi and 
Mutungi show that DHT also has a profound effect on regulating SNAT2 activity (Hamdi 
and Mutungi, 2010). However, anabolic steroids such as testosterone and its active 
metabolite, Dihydrotestosterone have not been extensively studied in regard to their 
effects on SNAT2 in aged animals (Hamdi and Mutungi, 2011). We theorise that a 
baseline anabolic signal is necessary for the proper functioning of these amino acid 
transporters. 
Regardless of whether the stimulation is hormonal, amino acid deprivation or osmotic 
shock, the efficacy of SNAT2 does not change in response to any form of stimulation. 
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This is proven by an observed increased Vmax (maximal transport) rather than Km 
(Franchi-Gazzola et al., 2006, Gaccioli et al., 2006, Kashiwagi et al., 2009). This means 
that the upregulation in SNAT2 transport can be solely accounted for by the quantity 
of functioning SNAT2 transporter on the plasma membrane. This makes quantification 
of SNAT2 function relatively easy, the transport of a given substrate being proportional 
to the expression of SNAT2 protein.   
1.3.2 LAT2 
LAT2 is a system L amino acid transporter of the Slc7 gene family. It is a relatively 
recently identified membrane transporter (Pineda et al., 1999). It cannot use a sodium 
gradient to drive transport but rather exchanges small neutral amino acids for the 
larger branched-chain amino acids such as leucine and histidine which are essential for 
protein synthesis in skeletal muscle (Hamdi and Mutungi, 2011). This is called tertiary 
active transport and it relies on the presence of sodium coupled amino acid 
transporters such as SNAT2. LAT2 has overlapping specificity in transporting smaller 
amino acids, thus being able to utilise the gradient created by SNAT2 to transport in 
the larger amino acids (Verrey, 2003). 
Structurally LAT2 is composed of a light chain which makes a functional heterodimer 
with aheavy chain, together acting as a transmembrane glycoprotein (Ikotun et al., 
2013). As illustrated in 1.3.2 Pochini et al. (2014) have used Scan-Prosite protein 
modelling software to map homogeneity of rodent LAT2 showing 92% overlap with the 
human LAT2. This analysis has also identified two potential phosphorylation domains 
of PKC and PKB, possibly hinting at a transceptor function of LAT2. More research 
needs to be done to elucidate the function and validity of these sites.  
Because LAT2 is responsible for the transport of large branched chain amino acids, it 
plays a vital role in regulating protein synthesis and plays a role in disease. LAT2 has 
been found to be upregulated in cancer cells and high expression levels of LAT2 are 
correlated with poor outcomes (Fuchs and Bode, 2005). This has led some to believe 
that LAT2 is a suitable target for cancer therapy or diagnosis (Sakata et al., 2009). LAT2 
has been proposed as a biomarker of advanced malignancy of prostate and brain 
tumours (Nawashiro et al., 2006, Sakata et al., 2009).  
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1.3.3 Relationship Between SNAT2 and LAT2 
There is strong evidence that the System A and System L transporters are coupled, 
relying on each other to maintain the intracellular amino acid pool (Meier et al., 2002, 
Ramadan et al., 2007). SNAT2 transports small neutral amino acids into the cell 
alongside sodium in 1:1 ratio. This drives the internal small AA pool that enables LAT2 
to transport large neutral amino acids into the cell in exchange for transporting one 
small neutral AA out of the cell in a 1:1 ratio (Hyde et al., 2007).  This possible 
relationship is illustrated in figure 1.3.3. To date, little is known about the effects of 
age on the number and function of these amino acid transporters in mammalian 
skeletal muscle fibres. It is also yet uncertain whether the coupling between SNAT2 
and LAT2 is affected by ageing. When considering the interplay between SNAT2 and 
LAT2 transporters, it is important to note the difference in substrate specificity. Below 
is a table illustrating the amino acid substrates of the SLC family of transporters. 
Table 2: Specificity of SNAT and LAT family of transporters 
 
 
 
 
 
SYSTEM PROTEIN GENE AA SUBSTRATES 
A SNAT1 SLC38A1 Me-AIB, Gly, Ala, Ser, Cys, Gln, 
Asn, His, Met, Thr, Pro, Tyr, Val  
A SNAT2 SLC38A2 Me-AIB, Gly, Pro, Ala, Ser, Cys, 
Gln, Asn, His, Met  
A SNAT3 SLC38A3 His, Lys, Me-AIB, Ala, Cys 
A SNAT4 SCL38A4 Gly, Pro, Ala, Ser, Cys, Asn, Met, 
His, Lys, Arg  
L LAT1 SLC7A5 Leu, Iso, Val, His, Met, Leu, Ile, 
Val, Phe, Tyr, 
Trp, Gln 
L LAT2 SLC7A8 Leu, Iso, Val, 
20 
 
 
 
 
 
 
 
 
Figure 1.3.3 Diagram of SNAT2 (green) and LAT2 (blue) transporters. SNAT2 is driven on a 
sodium gradient, established by the Na+/K+ ATPase (red). SNAT2 transports 1 molecule of Na+ 
per 1 small amino acid such as glycine into the cell. LAT2 in turn utilises the gradient of small 
amino acids to exchange one of these for a larger amino acid such as leucine. In this way 
SNAT2 maintains the function of LAT2, which in turn supplies the cell with larger, bulky side 
chain containing amino acids ensuring the cell has the complete array necessary for protein 
synthesis. Image produced using Adobe Flash.  
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1.4 Vesicular Trafficking 
One of the earliest and most studied examples of vesicular involvement in membrane 
transporter recruitment is that of GLUT4 trafficking. GLUT4 or glucose transporter 4, is 
a membrane bound transporter of glucose. It belongs to the SLC family of solute 
carrier proteins, of which SNAT2 is a member. GLUT4 is known to be upregulated by 
insulin, which triggers a recruitment of already formed GLUT4 from an intracellular 
vesicular pool (Leto and Saltiel, 2012). Insulin binding at the membrane insulin 
receptor sets of a cascade involving PI3K, Akt/Pkb, and Rab10 (Sano et al., 2007). 
The exact system of GLUT4 vesicular storage is unclear as of yet. However, it appears 
that the bulk of unrecruited GLUT4 resides in GLUT4 specific vesicles. These can either 
fuse with the plasma membrane directly or fuse with endosomes, which then in turn 
fuse with the plasma membrane (Chen and Lippincott-Schwartz, 2013). The vesicular 
sorting protein, Sortilin plays a role in trafficking of GLUT4 into stationary pools for 
later use (Hatakeyama and Kanzaki, 2011).  This response is rapid and profound, 
resulting in up to a 30-fold increase in functional transporter on the plasma membrane 
(Muretta et al., 2008). 
The effects of GLUT4 recruitment can be seen in under 30 minutes, underlying the 
rapid timeline of the recruitment process in the case of this transporter. The signalling 
between different GLUT4 pools is also tightly controlled. RABs are small GTPases 
involved in membrane trafficking. It has been shown that RAB14 ferries GLUT4 into 
special storage vesicles, while RAB10 in conjunction with its activating protein AS160 is 
responsible for the accumulation of these storage vesicles at the plasma membrane 
(Sadacca et al., 2013). These storage vesicles accumulate at the highest concentrations 
on T-tubules in skeletal muscle. Interestingly, in vivo studies of insulin mediated GLUT4 
recruitment showed that there is very little actual movement of vesicles throughout 
the cell. Rather, the nuclei serve as a main storage site for GLUT4 while secondary 
smaller vesicles deplete stored transporter in response to hormonal stimuli (Lauritzen 
et al., 2008).   
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Comparatively little work has been done in elucidating the mechanism of recruitment 
of SNAT2 or LAT2 but we can speculate that a similar level of complexity and feedback 
is involved in their recruitment and trafficking. Hyde et al. (2007) has shown evidence 
for a vesicular pool model of LAT, but this has been in response to insulin rather than 
anabolic signalling. Figure 1.4 illustrates the function and localisation of GLUT4 
transporters. More work is needed to elucidate the underlying mechanisms of these 
two amino acid transporters, which are vital to the function of skeletal muscle.  
 
Figure 1.4 Diagram of GLUT4 trafficking system. GLUT4 vesicles are located predominantly 
around the nuclei and t-tubules. These release transporters locally to fuse into the plasma 
membrane. Signalling in GLUT4 recruitment is mediated by PI3K and predominantly stimulated 
by insulin binding with the insulin receptor (IRS). Adapted from: (Lauritzen et al., 2008). 
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1.5 Anabolic Steroids 
Sex steroids are vital regulators of body shape, structure and composition in mammals 
(Bhasin and Buckwalter, 2001).  For example, treating adult female rats (Exner et al., 
1973), hypogonadal men (Bhasin et al., 1997) and elderly men with low testosterone 
concentrations (Ferrando et al., 2002) with testosterone or any of its numerous 
synthetic derivatives has been shown to increase lean body mass. This suggests that 
sex steroids are essential for the normal maintenance of skeletal mass and may be 
instrumental in the treatment of sarcopenic muscle dysfunction. 
Anabolic steroids as therapeutic interventions have been used and are still employed 
for numerous clinical purposes. The most prevalent is the treatment of hypogonadism, 
or physiologically low levels of androgens, as hormonal replacement therapy in males. 
Testosterone has also been shown as a beneficial treatment as an add on to female 
hormone replacement therapy, showing a protective effect against breast cancer 
(Glaser and Dimitrakakis, 2015). They were and still are used for the treatment of 
anaemias, most commonly aplastic anaemia (Basaria and Dobs, 2001). Patients with 
wasting conditions, such as HIV often respond well to these drugs which preserve lean 
body mass and increase appetite(Grunfeld et al., 2006).    
Testosterone, is often regarded as the principal male hormone. Produced mainly (95%) 
by the Leydig cells of the male testes, it then undergoes many metabolic changes. 
(Brooks, 1975) Figure 1.5.1 shows the metabolic pathways testosterone undergoes to 
produce the active DHT metabolite. The concentration of free testosterone in plasma 
decreases with age in both men and women (Mooradian and Korenman, 2006). 
Testosterone supplementation has been shown to increase lean body mass, as well as 
also increasing the number of nuclei per muscle fibre (Eriksson et al., 2005). Long term 
administration with anabolic steroids causes morphological changes in human skeletal 
muscle even after stopping treatment, the most long lasting being increased nuclei 
density (Yu et al., 2014).  
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Figure 1.5.1 DHT metabolism in the liver. 5α-reductase converts Testosterone into the much 
more potent DHT. 3α-hydroxysteroid dehydrogenase converts DHT into the much less active 
3α-diol derivative. Both enzymes are expressed in peripheral tissue, indirectly controlling the 
extent of anabolic activity. UDP-glucoronyl transferase is predominantly found in the liver. 
Adapted from (Pirog and Collins, 1999). 
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Testosterone however,  is not the most potent sex steroid in the body (Gruenewald 
and Matsumoto, 2003). Instead, in certain target tissues such as the skin, prostate and 
brain, it is irreversibly metabolised to dihydrotestosterone (DHT) by the enzyme 5alpha 
(α)-reductase (Bruchovsky and Wilson, 1968). This metabolite of testosterone, has 
proven itself to be a much more potent androgen. It has been shown that it takes 
roughly 10 times the amount of testosterone to elicit the same increase in 
transcription as seen with DHT administration (Grino et al., 1990). This is due to the 
binding kinetics of DHT to the androgen receptor (Saartok et al., 1984). Recent studies 
from our laboratory have shown that DHT but not testosterone increases maximal 
isometric force and amino acid transport in fast-twitch muscles (Hamdi and Mutungi, 
2010, Hamdi and Mutungi, 2011, Wendowski et al., 2016). However, whether skeletal 
muscle expresses 5α-reductase necessary for the conversion into DHT has not been 
conclusively shown. It is also unclear whether DHT can reverse the effects of age on 
protein synthesis in skeletal muscle, as there is little work done using DHT treatment 
on elderly populations.  
1.5.1 Steroid Mode of Action 
Steroid hormones are classically thought to act by travelling through the plasma 
membrane to activate a cytoplasmic androgen receptor (AR). The AR is a protein of 
110 kDa in size, consisting of 919 amino acids in 12 α-helices and 2 β-sheets (Rochette-
Egly, 2003).  
The AR is normally bound to other chaperone proteins which prevent enzymatic 
damage, one of which is heat shock protein 90 (Pratt and Kinch, 2003, Pratt and Toft, 
2003). The binding of androgens to the AR causes a conformational change, which 
leads to detachment of chaperone proteins and exposes a nuclear localisation domain 
causing the AR-androgen complex to translocate into the nucleus (Gelmann, 2002). 
This complex then acts on transcription factors on specific DNA elements in target 
genes, resulting in either the activation or suppression of transcription. The DNA 
binding domain of this complex then interacts with hormone responsive elements on 
target genes, which can either lead to activation or repression of these genes (Losel 
and Wehling, 2003).  
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The genomic effect of anabolic steroids peaks several hours after administration (Cato 
et al., 1988). After this increase in transcription, it is necessary to translate the mRNA 
into proteins, which then must be processed before they are usable and cause an 
observable physiological effect in the cell. It was because of this, that steroids were 
ordinarily thought to work on a timeframe of days rather than hours. This from herein 
will be referred to as the genomic action of anabolic steroid hormones.  
However, we now know that steroid actions are not limited to this pathway. In 
addition to the classical idea of androgen binding to nuclear receptors, androgens have 
been proven to elicit their effects on tissue through non-genomic pathways (Dubois et 
al., 2012). This will be herein referred to as the non-genomic action of steroid 
hormones. Both anabolic steroids and corticosteroids have shown to elicit measurable 
effects after an hour of administration. The most studied non genomic action of 
steroids is the acute rise in calcium concentration, which is seen in response to not 
only androgens (Gorczynska and Handelsman, 1995, Benten et al., 1999) but in fact all 
classes of steroids (Lieberherr et al., 1993, Audy et al., 1996, Benten et al., 1997). An 
experiment by Wunderlich et al (2002), showed that in murine macrophages lacking 
intracellular AR testosterone was able to ellicit an intracellular calcium concentration 
increase. This was also accomplished with a testosterone and BSA conjugate, which 
cannot cross the plasma membrane. This suggests that the androgen receptor at work 
is associated with the membrane and able to bind molecules outside the cell. In 
addition to binding to a membrane associated AR receptor other proposed non-
genomic modes of action of androgens involve acting directly or indirectly on G-
protein receptors or intracellular kinases (Foradori et al., 2008, Dent et al., 2012).  
1.5.3 Signalling Kinases 
There is evidence from the work in our lab on skeletal muscle that some of the non-
genomic actions of androgens are mediated, at least in part by EGFR phosphorylation 
and further EGF signalling through the ERK1/2 pathway (Hamdi and Mutungi, 2010, 
Hamdi and Mutungi, 2011). More recently, DHT was found to potentiate the action of 
EGF in lung fibroblasts leading to significant increases in ERK signalling (Lee et al., 
2014). It is unclear however, whether this effect involves the initial binding of an AR   
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element, as work with prostate cells has shown androgen receptor blockers to 
completely abolish this effect, while in the previous work by Hamdi et al. it has not 
shown total inhibition (Oliver et al., 2013). Interestingly, work by both groups has 
shown this effect to be specific to Dihydrotestosterone. Testosterone administration 
alone failed to induce these effects (Zhou et al., 2015b).  
The SRC family of kinases has also been found to be involved in acute DHT signalling. 
Both SRC and epithelial growth factor receptor (EGFR) are phosphorylated in response 
to DHT (Lee et al., 2014).  
Although the exact nature of non-genomic binding of androgens remains to be 
elucidated, the data from our lab strongly suggests the involvement of the EGFR. It is 
unknown whether androgens are capable of direct binding to the EGFR domain or a 
proximal androgen sensitive domain. DHT has been shown to greatly potentiate the 
effect of EGF, but does not elicit an action in the absence of EGF (Lee et al., 2014). This 
suggests that an AR domain is interacting with the EGFR to co-activate the MAPK/ERK 
signalling cascade. There is evidence of this interaction between AR and the EGFR, 
showing that androgen binding has direct effects on the magnitude of signalling in 
response to EGF (Bonaccorsi et al., 2004). It has recently been shown that baseline EGF 
levels are necessary not only for development, but also for the maintenance of healthy 
ageing muscle by controlling protein homeostasis (Rongo, 2011). 
Mitogen activated protein kinases are the correct term for ERKs (extracellular signal-
regulated kinases). The pathway is initiated with the phosphorylation of the EGFR 
receptor. The process continues with GRB2 containing a SH2 domain that then binds at 
phospotyrosine residues on the activated EGFR. This then binds to guanine nucleotide 
exchange factor SOS. GRB2-SOS is activated by phosphorylated EGFR, then going on to 
remove a molecule of GDP from Ras kinases. Ras goes on to activate RAF kinase 
cascade, which causes a phosphorylation and activation of MEK1/2 and MAPK 
(McCubrey et al., 2007). 
RAS-RAF-MEK-ERK-MAPK signalling is instrumental in maintenance of protein synthesis 
and healthy muscle function.  It is also a potential drug target for the treatment of 
malignancy (McCubrey et al., 2007, Sebolt-Leopold, 2008). As this pathway controls  
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cell growth, it is often upregulated in cancer cells and this upregulation serves as a sign 
of worsened prognosis (Hew et al., 2016).  
1.5.4 Impact of Ageing 
It is well documented in human and animal models that endogenous testosterone 
production decreases with age (Harman et al., 2001, Feldman et al., 2002, Chen et al., 
2015a). This is observed as a gradual decline from around the age of 25, followed by a 
sharp decline in serum testosterone in old age. This is most likely due to lesions 
formation in Leydig cells of the testes resulting in decreased output of anabolic 
hormone (Midzak et al., 2009). This reduction of testosterone predisposes both males 
(Matsumoto, 2002) and females (Carcaillon et al., 2012) to greater risk of falls resulting 
in disability, reduced independence and overall lower standard of living. This can be 
otherwise characterised as sarcopenia.  
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1.6 Sarcopenia 
Sarcopenia, stemming from the Greek sarco meaning flesh and penia meaning poverty 
refers to skeletal muscle wasting due to old age, is a condition that is characterised by 
the progressive and gradual (at a rate 1-5% per annum depending on age) decline in 
skeletal muscle mass, strength and function (Frontera et al., 1991).  In humans we 
observe a gradual but slow decrease in muscle mass from around the age of 30 (Ryall 
et al., 2008). While statistically significant, this loss does not normally lead to any 
functional decline until much further into old age. At an average age of just over 70, 
the prevalence of sarcopenia was found to be 36.5% (Brown et al., 2016). 
Sarcopenia manifests itself predominantly in the elderly population and leads to 
inactivity, increased susceptibility to falls and eventually to the loss of independent 
living (Morley et al., 2001). Falls especially, are a major health concern because they 
lead to hospitalisation and increased mortality in the elderly. This of course means a 
significant financial burden on the NHS. However, despite its profound socioeconomic 
implications, the exact causes and mechanisms underlying sarcopenia are still poorly 
understood at present. In addition to causing movement related debilitation, the onset 
of sarcopenia has also been linked with a decline in cognition associated with 
dementia and Alzheimer’s disease (Mori et al., 2016). 
Several groups have attempted to define sarcopenia in humans. The most robust 
consensus definition today is approved by the European Working Group on Sarcopenia 
EWGSOP (Cruz-Jentoft et al., 2010b). It is defined in its severe form as a measured 
muscle mass of over 2 standard deviations below the average in young adults of same 
sex and ethnicity, an abnormally low gait speed, and low muscular strength measured 
by resistance exercise. See Fig 1.7 for a proposed EWGSOP diagnosis algorithm (Cruz-
Jentoft et al., 2010a). 
There is no definitive treatment protocol that has proven to be effective for sarcopenic 
muscle dysfunction. Testosterone has been used successfully, but also causes a 
number of side effects, including prostate growth and alopecia(Wakabayashi and 
Sakuma, 2014). Growth hormone (GH) seems to be ineffective for increasing muscle   
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strength, likely due to a reduction in mRNA levels of GH receptor in elderly populations 
(Sakuma and Yamaguchi, 2012). Myostatin blockers and SARMS (selective androgen 
receptor modulators) remain an appealing option, but study of these compounds in 
treating sarcopenia is still limited and stricter guidelines need to be established for 
running drug treatment studies for sarcopenia (Reginster et al., 2016). There is scarce 
data on the use of DHT rather than testosterone in elderly models.  
As stated above, the reduction in testosterone seen with ageing has been widely linked 
to sarcopenia. This occurs in males as well as females (Carcaillon et al., 2012). This 
reduction is not only linked to dysfunction in skeletal muscle. It is also implicated in 
osteoporosis, leading to impaired bone density and higher incidences of fractures (Fink 
et al., 2006). The combination of increased risk of falls due to fast twitch fibre loss 
coupled with the decrease in bone density is especially perilous in elderly populations.  
Genetic variations among individuals also play an important role in determining the 
magnitude of anabolic stimuli available to skeletal muscle. For instance, variants on the 
SHBG and X chromosome are strongly associated with low concentrations (<300ng/dl) 
of testosterone in man (Ohlsson et al., 2011). These mutations are also implicated with 
an increased risk of developing sarcopenia in older age.  
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Figure 1.7 Accepted algorithm of sarcopenia diagnosis is based on a combination of functional 
tests and muscle mass. Adapted from: (Cruz-Jentoft et al., 2010a). 
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1.7 Thesis Aims 
The aims of the thesis are: 
Aim one: To assess the effects of normal ageing on total and relative muscle weights of 
the soleus and EDL, and the expression and transport of the sodium-coupled neutral 
amino- amino acid transporter SNAT2 and the sodium-independent L-type amino-acid 
transporter LAT2, and quantify protein incorporation. To also quantify the extent of 
change in AA transport with ageing and to relate these findings to the onset of 
sarcopenia.  
Aim Two: To assess whether treatment with DHT can be an effective intervention for 
the reversal of SNAT2 and LAT2 related muscle dysfunction associated with ageing. To 
propose a likely mechanism for the DHT response.  
Aim Three: To study the relationship between SNAT2 and LAT2 in mice skeletal muscle. 
To artificially increase the quantity of functional SNAT2 as well as to block it, then 
subsequently measure the effects of this intervention on LAT2 activity. Relate findings 
to the ability to modulate LAT2 activity through SNAT2. 
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Chapter 2: Materials and Methods 
2.1 Buffers 
AMPS: 100mg Ammonium Persulphate in 1mL distilled water. TE buffer 10 mM Tris-Cl, 
1 mM EDTA, adjusted to pH 7.5. 
Differentiation Media: MEM stock, 30mg/ml L-Glutamine (Invitogen, UK 11880-028) 
1% Streptomycin/1% Penicillin (Invitogen UK 15140-122), 2% Horse Serum (Thermo-
Fisher UK SR0035C). 
Elution solution: 1.0M Tris buffer with sodium chloride, EDTA; adjusted to pH 7.4.  
GTE buffer: 50 mM Glucose, 25 mM Tris-Cl, 10 mM EDTA, adjusted to pH 8. 
HBSS: Hanks Balanced Solution (Invitogen UK 24020). 
IP wash buffer: Wash 10mM Tris; adjust to pH 7.4, 1mM EDTA , 1mM EGTA; pH 8.0 
150mM NaCl , 1% Triton X-100, 0.2mM sodium orthovanadate, Protease inhibitor 
cocktail. 
Laemmli buffer: 1 mL Glycerol, 1g SDS 10%, 6.25 mL Tris HCl 0.5M pH 6.8, 2.5 mL  β-
mercaptoethanol, 1 mL Bromophenol 0.5%, made up with 10 mL of distilled water. 
Mild Stripping Buffer:  1 liter 15 g glycine 1 g SDS 10 ml Tween20 adjusted to pH 2.2. 
NP40 Lysis Buffer: 150mM NaCL, 50mM Trsibase, 1.5mM MgCl2 10% Glycerol, 1% NP-
40, 1mM EDTA, pH calibrated to 7.5 with HCl. 
PBS 10X: 40g  NaCl,1g KCl, 13.4 g  Na2HPO4-7H2O, 1.2 g H2O, pH adjusted to 7.4, made 
up to 500ml with distilled water. 
Ringer Solution: 109mM NaCl, 5mM KCl, 1mM MgCl2, 4mM CaCl2, 24mM NaHCO3, 1 
NaHPO4, 10 sodium pyruvate plus 200 mg l−1 bovine calf serum; and its pH was 
maintained at 7.42 by constantly bubbling it with 95% O2 and 5% CO2.  
RIPA buffer: 150 mM sodium chloride, 1.0% NP-40, 0.5% sodium deoxycholate, 0.1% 
SDS, 50 mM Tris, then made up to pH 8.0 with HCl. 
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Running Buffer 10x: 30.3g Trisbase, 144g Glycine, 10g SDS, pH calibrated at 8.3 and 
made up to 1000mL. 
SDS lysis solution: 0.2 M NaOH, 1% SDS. 
Standard Culture Media (DMEM): (DMEM) 4500 mg/L glucose, Invitogen DMEM stock, 
30mg/ml L-Glutamine (Invitogen, UK 11880-028), 10% FBS (Invitogen, UK  16000044) 
1% Streptomycin/1% Penicillin (Invitogen UK 15140-122). 
TBST 10X: 250mM Trisbase, 1.4M NaCl, 30mM KCl. 
Transfection Media: DMEM, Lipofectamine 3000 (Therfmo Fisher, USA) 75µL/ well. 
Transfer Buffer: 28.8 g glycine, 6.04g Trisbase, 200mL methanol, made up to 2L with 
water. 
Tris Buffer 8.8: 1.5M Trisbase, adjusted pH to 8.8 with HCl. 
Trisbase 6.8: 0.5M Trisbase, adjusted to pH of 6.8 with HCl. 
Wash buffer: 10mM Tris; adjusted to pH 7.4, 1mM EDTA, 1mM EGTA; pH 8.0, 150mM 
NaCl, 1% Triton X-100, 0.2mM sodium orthovanadate.  
Western Blot Running Gel 10%: 5.0ml Acrylamide 40%, 9.69mL distilled water, 5.0mL 
Tris HCl 8.8, 200uL 10% SDS, 100uL 10% AMPS, 10uL TEMED. 
Western Blot Stacking Gel 4%: 1.0mL Acrylamide 40%, 6.4mL Distilled water, 2.5mL 
Tris HCl 6.8, 100uL 10% SDS, 50uL 10% AMPS, 10uL TEMED . 
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2.2 Isolation of small skeletal muscle fibre bundles 
2.2.1 Animal Husbandry 
The mice cohort used for these experiments consisted of CD-1 female mice of specified 
ages. The mice were maintained at the DMU (Disease Modelling Unit), University of 
East Anglia. They were kept at a maximum of 4 mice per cage and exposed to 12hrs of 
daylight and 12hrs of darkness. The mice were fed a diet of standard rodent chow and 
water ad libitum.  
CD-1 mice strain was chosen due to the minimal incidence of genetic complications 
and genotype diversity comparable to a normal murine population (Aldinger et al., 
2009). Relatively short lifespan of CD-1 mice makes them suitable for ageing studies.  
The mice were regularly inspected for signs of disease or stress and recorded weights 
matched those of healthy CD-1 populations at given ages (Percy and Jonas, 1971). No 
animals with signs of illness were used for data collection. 
2.2.2 Fine Dissection 
All the experiments reported were performed at room temperature (~20°C) using 
small skeletal muscle fibre bundles isolated from the extensor digitorium longus (EDL, 
a fast-twitch muscle in adult mice) and the soleus (Sol, a predominantly slow-twitch 
muscle in adult mice) of young (~100 days old), middle aged (300-400 days old) and 
elderly (>700 days) female CD-1 mice. Animals were killed by the Schedule 1 method of 
cervical dislocation as recommended by the Home Office and compliant with The 
Animal Scientific Procedures Act of 1986. For summary of the legislation see 
Drummond. (Drummond, 2009). Additionally, the experiments conformed to the 
University of East Anglia Animal Welfare and the Ethical Review Board guidelines on 
animal treatment. Approval for the project was sought from the AWERB and approved 
for the use of licensed procedures to be performed by licensed individuals. However, 
during the project, the mice were not subjected to any procedures and were sacrificed, 
after which muscle tissues were extracted. The number of animals used was minimised 
to the lowest level possible whilst still allowing for significance testing.  
Dissections were done as promptly as possible. SOL was isolated as a whole muscle, 
while the EDL was split into its three constituent bundles to isolate the most 
predominantly fast twitch bundle (medial bundle). Care was taken to ensure the fibres 
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were intact and responsive to electrical stimulation for the duration of the 
experimental runs. Fibres were tested for contractility after isolation using low voltage 
stimulation, repeated every 2 seconds prior to start of the experiment. 
2.2.3 Experimental Procedure 
During the experiments, the muscles and muscle fibre bundles were bathed in 
mammalian Ringer’s solution continuously bubbled with 95% O2 and 5% CO2 gas to 
maintain a physiological pH of 7.4 or 80% 02 and 20% CO2 to achieve an acidic pH of 
6.8.  Ringers solution was based on prior formulations by Mutungi and Ranatunga 
(2000), (for composition see materials) and its pH was maintained at 7.42 by constant 
bubbling.  
Figure 2.2.1 Example of the tissue baths used for uptake testing. Hooks rotate freely to allow 
access to muscle. Ringer’s solution submerges tissue fully and is constantly bubbled with CO2 
to maintain physiological pH.  
 
Two types of muscle chambers, one with a total volume of 5 ml and 25 ml, (25mL 
shown in figure 2.2.1) were used for the determination of amino acid uptake and 
muscle tissue treatments. The fibre bundles were continuously perfused with the 
standard mammalian Ringer solution to ensure muscle tissue viability.  For the 
duration of uptake experiments the muscle fibres were mounted horizontally in 
between stainless-steel hooks in the specially designed muscle chambers.  
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2.3 SDS-PAGE analysis 
2.3.1 Experimental Setup 
SDS-PAGE was used to investigate the acute effects of DHT on the expression of AA 
transporters. In an effort to reduce variability and destruction of aged mice, one set of 
EDL and SOL from each mouse was subjected to control and the other set was treated 
with DHT. Tissue from a minimum of 3 different mice was used in each individual 
experimental cohort to achieve n≥3.  
Group 1 (controls) was treated with 107.9μM ethanol in Ringers solution (the vehicle 
used to dissolve DHT) for 1hr. Group 2 (experiment) was treated with 2.17nM of DHT 
for the 1hr plus 107.9μM ethanol in Ringers solution.  
At the end of the treatments, the bundles were snap frozen in liquid nitrogen and 
pulverized in eppendorf with plastic tissue grinder (Fisher Scientific, UK), then placed in 
100µl of NP40 buffer (see buffers 2.1.1) containing 10mg/10mL protease (Roche, 
Switzerland) and 100µl/10mL phosphatase inhibitors (Calbiochem, Nottingham). These 
were then further agitated with rotary tissue grinder to homogenise.  
2.3.2 Sample Preparation 
Crude membrane fraction was isolated from lysate using NP-40 buffer cellular 
membrane fractionation by centrifugation at 15000g for 10min at room temperature, 
washing three times with PBS and then resuspension of resulting pellets in 100µL of 
NP-40 buffer as first described by Holden et al. (2009) (Perez et al., 2013). The lysates 
from the resuspension step contained the desired crude membrane fraction and kept 
for use in further experiments. Samples were then stored at -80°C or used 
immediately.  
Protein concentration was determined by preparation of 5µL of each lysate with 100µL 
of Bradford reagent (Sigma-Aldrich, Dorset UK) The Bradford reagent is a dilution of 
Coomassie brilliant blue G-250 dye (CBBG). This was then compared alongside a 
calibration curve of varying concentrations of Bovine Serum Albumin (BSA) to perform 
a Quick Bradford Assay (Bradford, 1976). Concentrations of BSA used were 0,1,5,10 
and 20µL using a 1mg/mL BSA stock. The reagents were dissolved in double distilled 
water in 1mL disposable cuvettes and then inverted three times to ensure thorough   
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mixing. A spectrophotometer (Helios Y, Fisher Scientific, UK) was used to read 
absorbance of samples at a wavelength of 595nm. The Quick Bradford technique 
provided an accurate and fast method of quantifying lysate protein concentrations.  
10µg of total protein (as calculated from results of Quick Bradford analysis on 
extracted lysates) was pipetted into empty eppendorfs. Each of these were then mixed 
with 5µL 2x Laemmli buffer containing 10% β-mercaptoethanol  (see buffers 2.1.1 ). 
Samples were boiled at 100°C for 2 minutes prior to centrifugation for 30 sec at 
13,000rpm and loaded into each well of a 12% SDS-PAGE gel. Finally, 1µL of protein 
ladder was (ab116028, Abcam, USA) added to the first well of every gel.   
2.3.3 Casting and Running Gels 
Gels were produced according to the following formula: 
Table 3: SDS-PAGE Gel Composition 
12% gels were found to be most suitable for running both SNAT2 and LAT2 proteins. 
Gels were inspected for conformity and well formation. These were either used after 
casting or refrigerated at 4-8°C and used within 14 days. Samples were separated by 
standard gel-electrophoresis using Mini-Protean Tetra-Cell (BioRad Laboratories, 
Hemel Hempstead) and ran in transfer buffer (see buffers 2.1.1) at 90V for 3-4hrs until 
proteins ran to close proximity of  the bottom of the gel. 
 Precut PVDF membranes were soaked in methanol for 10 minutes. The finished gels 
were then placed onto the PVDF membranes and placed in a Trans-Blot Semi-Dry 
Transfer Cell, (BioRad Laboratories, Hemel Hempstead) These were then transferred 
onto the PVDF membranes by running the semi dry transfer system for 40 minutes, at   
Ingredient 12% Running Gel 4% Stacking Gel 
ddH20 9.69mL 6.4mL 
Acrylamide 40%  5mL 1mL 
Trisbase (pH 8.8) 5mL 0 
10% SDS 200µL 100µL 
AMPS 100µL 50µL 
TEMED 15µL 10µL 
Trisbase (pH6.8) 0 2.5mL 
Total Volume 20mL 10mL 
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250V and 0.2 Amperes. After completion, membranes were placed in TBST (see buffers 
2.1.1) and refrigerated at 4-8°C for storage.  
The membranes were blocked for non-specific antibody binding using 5% milk in TBST 
for 10 min. They were then analysed for the expression of SNAT2 (rabbit polyclonal; 
Santa Cruz Biotechnology, Santa Cruz, Ca, USA) or  LAT2 (rabbit polyclonal; Abcam, 
Cambridge, UK). Primary antibodies were incubated at a 1:500 dilution for a minimum 
of 2hrs (SNAT2) or overnight at 4°C (LAT2) under rocking. Anti-rabbit secondary 
antibodies conjugated to horse radish peroxidase (HRP) were used at a 1:2500 dilution 
and incubated for 1hr at room temperature.   
Membranes were washed in TBST (see materials twice and then left under rocking for 
10min, this was then repeated three times. Finally, they were visualized using 
SuperSignal WestPico chemiluminescence substrate (Perbio Science UK Ltd, 
Cramlington and Northumberland, UK) and exposure was done on ChemiDoc XRS+ 
(Bio-Rad, Watford,UK).  
The following day, the membranes were stripped with mild stripping buffer for 20min 
under rocking (see buffers 2.1.1) and re-probed with a pan-actin antibody (Mouse 
monoclonal, Abcam, Cambridge, UK). Actin antibody was used at a 1:2000 dilution and 
incubated for 1hr at room temperature. Secondary HRP conjugated antibody (Goat 
anti-mouse, Abcam, Cambridge, UK) was used at dilution of 1:5000 for 1hr at room 
temperature. All the blots were run in duplicates and each experiment was performed 
a minimum of three times, each using proteins from a different animal.  
Table 4: Antibodies used in Western Blotting 
Antibody Target Dilution Supplier Code Supplier 
SNAT2 (Rabbit 
Polyclonal) 
1:500 (WB) sc-67081 Santa Cruz 
Biotechnology, Santa 
Cruz, Ca, USA 
LAT2 (Rabbit 
Polyclonal) 
1:500 (WB) ab123893 Abcam, Cambridge, UK 
Secondary antibody 
(Goat Anti-Rabbit IgG 
HRP conjugated) 
1:2500 (WB) ab6721 Abcam, Cambridge, UK 
Anti Actin (Mouse 
Monoclonal) 
1:2000 (WB) ab3280 Abcam, Cambridge, UK 
Secondary Antibody 
(Goat Anti-Mouse IgG 
HRP conjugated)  
1:5000 (WB) ab97040 Abcam, Cambridge, UK 
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2.4 Reverse transcription quantitative polymerase chain reaction (RT-
qPCR) 
2.4.1 Sample Preparation 
Total RNA extraction from fast-twitch and slow-twitch muscle fibre bundles was 
performed using TRIzol® reagent according to the manufacturer’s instructions 
(Lifetechnologies, Paisley, UK). The muscle samples were snap frozen in liquid nitrogen, 
then pulverised and mixed with 100µl ice cold TRIzol. The mixture was centrifuged at 
12,000g for 10min at 4°C and the supernatant was transferred into a new tube. It was 
mixed with chloroform and incubated for 3 minutes at room temperature before it was 
centrifuged at 12,000g for 15 min at 4°C. The aqueous phase was separated, mixed 
with isopropanol then left to incubate at room temperature for a duration of 10min. It 
was centrifuged at 12,000g for 10 at 4°C and the precipitated RNA was purified from 
contaminants using  an RNeasy Mini Kit (Qiagen, Manchester, UK) and dissolved in 
RNAse-free water and stored for further use. The quantity and quality of the RNA 
extracted was determined spectrophotometrically using a Nanodrop 2000 
spectrophotometer (Thermo Fisher, Massachusetts U.S.A.). 1µg of RNA was reverse 
transcribed using Quantitect Reverse Trancriptase to generate cDNA following the 
manufacturer’s standard protocol (Qiagen 2009). SYBR green Readymix (Sigma-Aldrich, 
Irvine UK) was used for cDNA amplification, setup as follows: 
Table 5: PCR Experimental Composition 
Component         
Experimental 
No Template 
Controls 
No RT Control 
SYBR Green qPCR Readymix 
(2x) 
             10µL           10µL              10µL 
Forward Primer (10µM 
stock) 
             0.4 µL           0.4 µL              0.4 µL 
Reverse Primer (10µM stock)              0.4 µL           0.4 µL              0.4 µL 
Template cDNA              5.0 µL            -------             5.0 µL  
(reverse transcriptase 
replaced with H2O) 
PCR Grade H2O             4.2 µL           9.2 µL             4.2 µL 
Total Volume            20 µL           20 µL            20 µL 
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2.4.2 Experimental Runs 
To test for DNA contamination, a no template control was used for each experimental 
run consisting of PCR grade H2O in place of cDNA template. A no reverse transcriptase 
control was used by omitting the reverse transcriptase in the cDNA generation step. 
Only experimental samples that resulted in no significant amplified products in the two 
corresponding negative controls were used. 
The PCR consisted of the following steps: 
Table 6: PCR Protocol Summary 
Step Temperature Time Times completed 
Initial Denaturation             94°C             2 min                 1 
Denaturation             94°C             15 sec               35 
Aneal and 
extension 
            55°C             1 min               35 
 
The primers used were as follows: 
SNAT2:  
Forward: 5’ ATCGTGGTGATTTGCAAGAA 3’ 
Reverse: 5’ GTCTGCGGTGCTATTGAATG 3’ 
LAT2 
Forward: 5’ GCCCTCACCTTCTCCAACTA 3’ 
Reverse: 5’ CCATGTGAGGAGCAACAAAC 3’ 
S29 (housekeeping gene standard) 
Forward    5’ CGGAAATACGGCCTCAATATG 3’  
Reverse    5’ CAACCAACAAGTTTATGCAACCA 3’ 
 
PCR equipment used for experimental protocol was the 7500 Real-Time PCR System 
(Applied Biosystems, Grand Island, NY). All the experiments were performed in 
triplicate and were completed a minimum of 3 times, each with a different animal. S29 
was used as the housekeeping gene for standardization. Melting curves were recorded 
and samples with peaks suggesting additional amplified entities were discarded (Fig. 
2.4). Representative melt curves as shown on following page. 
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igure 2.4 S29 and SNAT2 melting curves. Graphs showing representative melting curves of 
S29 (LEFT) and SNAT2 (RIGHT). There is no evidence of any secondary products being produced 
during the amplification.  
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2.5 Cell Culture 
2.5.1 General Cell Maintenance   
The cell line C2C12 is an immortal line of mouse skeletal myoblasts originally derived 
from the  satellite cells of a C3H mouse donor after an injury of the animals thigh (Yaffe 
and Saxel, 1977).  Cells used for all experiments were at passage 5 or below.    
C2C12 cells were kept in T25 culture flasks (Fisher Scientific, 
Loughborough, Leicestershire) at a temperature of 37°C and 95% O2, 5% CO2. Standard 
medium used was DMEM (Invitogen UK 11880-028) with added 10% fetal bovine 
serum, supplemented with 2mM L-glutamine and 1% streptomycin (Sigma-Aldrich, 
Poole, UK).  Cells were routinely monitored in order to not allow them to reach higher 
than ~80% confluence at which point they were split into additional flasks. Cells were 
detached from flasks using trypsin as follows:  
C2C12 cells were examined to ensure they did not exhibit signs of distress or 
contamination. Trypsin, HBSS and DMEM were prewarmed to 37°C, culture media was 
removed from the flasks. Cells were rinsed with HBSS (Ca+2 and Mg+2 free) and trypsin 
solution was used to dislodge any firmly adherent cells. Trypsin solution was added to 
submerge the bottom of the flask and swirled gently. After 2-3 minutes 2 volumes of 
DMEM was added to inactivate the trypsin. Resulting cell suspension was spun at 
500xg for 5 minutes and the cells were re-plated and DMEM replaced.  
2.5.2 Differentiation into Myotubes 
For differentiation into myotubes, myoblast cells were re-plated and allowed to grow 
for 3 days. At this point, the media was changed to MEM with 2% horse serum 
supplemented with 2mM L-glutamine and 1% streptomycin, (Invitogen UK 21090-022) 
and incubated overnight for 12hrs then changed to fresh MEM with 2% horse serum, 
2mM L-glutamine, and 1% streptomycin. This procedure initiates differentiation of the 
myoblasts into myotubes (Lawson and Purslow, 2000). Myotubes were inspected after 
3 days for differentiation and good health then used for experiments before they were 
allowed to reach confluence.  
2.5.3 DHT treatment  
Myoblasts were cultured in full media at 37C until 70-80% confluence. Myotubes 
were used 3 days after differentiation. DHT was used at 2.17nM (physiological) or 4nM   
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(supraphysiological). 107.9µM ethanol was used as DHT vehicle and added to DHT-free 
controls. Experiments were run at 37C in DMEM (myoblasts) or MEM (myotubes) in 
the presence or absence of DHT and in the presence of either 2mML C14Isoleucine or 
68.3μM C14MeAIB.  
T25 Flasks were kept in a sealed and heated container maintained at 37°C and bubbled 
with 95/5% O2/CO2 to maintain physiological pH. The experiment was completed over 
the course of 1hr to mirror skeletal muscle experiment conditions. At the end of the 
1hr experimental run, flasks were then washed three times with ice cold PBS and cells 
removed off using cell culture scrapers and PBS. These were then put into 5mL glass 
tubes, then centrifuged at 500 rpm to remove PBS. The pellet was resuspended in 
100µL of NP40 buffer and put on ice for 20min to encourage cell lysis. These were then 
pulverised using a rotary eppendorf grinder until pellet was homogenised and then 
spun at 13000g for 10min. Resulting pellet was discarded and the total cell lysate used 
for scintillation counting.  
2.5.4 Treatment with antagonists 
Myoblasts were cultured in full media at 37C until 70% confluence before start of 
experiments. Myotubes were used 3 days after differentiation. Cells were pretreated 
with antagonists for 1hr prior to starting experiment. Chloroquine was used at a 
concentration of 40µM, Flutamide at 3µM, SP600125 at 10µM and Wortmannin at 
200nM (see antagonists 2.1.3).  Experiments were all run at 37C in DMEM (myoblasts) 
MEM (myotubes) in the presence or absence of antagonists and in presence of either 
2mM C14Isoleucine (for LAT2 transport) or 68.3μM C14MeAIB (for SNAT2 transport). 
Flasks were kept in a sealed and heated container bubbled with O2/CO2 mixture to 
maintain physiological pH. Experiment was run over the course of 1hr. Flasks were 
then washed three times with ice cold PBS and scraped to remove cells. These were 
then centrifuged at 500 rpm to remove PBS and then lysed in NP40 buffer as described 
aboce (refere to section) .  
2.5.5 C2C12 cell starvation and SNAT2 blockade 
Myoblasts were cultured in full media at 37C until 70-80% confluence before start of 
experiments. For starvation cohorts, cells were placed in HBSS for 3hr prior to start of 
experiments. Experiments were then run at 37C in HBSS. SNAT2 was blocked using   
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saturating concentrations of 5mM and 10mM of MeAIB. as described by Hundal et al. 
(Hundal et al., 1994). 5mM was found to be the concentration necessary for saturable 
block of SNAT2. (see Chapter 5.) Cells were preincubated with saturating 
concentrations of MeAIB (as determined to be >5nM) for 1hr prior to start of 
experiments. Flasks were kept in a sealed and heated container bubbled with O2/CO2 
to maintain physiological pH. Experiment was ran over the course of 1hr. After 1hr, 
flasks were then washed three times with ice cold PBS and scraped to remove cells. 
These were then centrifuged at 500 rpm to remove PBS. These were then pulverised in 
NP40 buffer and centrifuged at 13500 rpm, pellet was discarded and total cell lysate 
used for scintillation counting as before.  
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2.6 Radio-Isotope Techniques  
2.6.1 LAT2 transport in Muscle 
Muscle tissues of various ages were treated with the standard Ringer’s solution 
containing 107.9µM ethanol plus 2mM C14 isoleucine containing a  radioactivity level 
of 3.46µCi/mL.  (PerkinElmer, Buckinghamshire, UK) for 1hr to assess LAT2 transport. 
Isoleucine was used because it alone does not increase protein synthesis, unlike 
Leucine (Anthony et al., 2000).  
The DHT treatment group was treated with the Ringer’s solution containing 2.17nM 
4,5α-dihydrotestosterone (DHT) (Sigma, Gillingham, Dorset, UK), 107.9µM ethanol, 
plus the C14 isoleucine for the same duration (1hr). During this time, the muscles were 
held in muscle chambers at 22°C, with constant bubbling to maintain physiological pH.  
At the end of the 1hr experiment, the fibre bundles were washed three times with ice 
cold PBS and the excess PBS was blotted on tissue paper. The bundles were 
immediately snap frozen in liquid nitrogen, pulverised and mixed with NP40 buffer 
containing 10mg/10mL protease (04693116001 Roche, Basel, Switzerland) and 
100µl/10mL phosphatase inhibitors (524625 Calbiochem, Nottingham). The mixture 
was centrifuged at 13,000g for 10min and the supernatant was collected and used for 
scintillation counting.  
2.6.2 Protein Incorporation in Muscle 
When assessing protein incorporation, 2mM C14 isoleucine was used as with LAT2 
transport protocol above.  The supernatant was further processed by mixed with ice-
cold 10% TCA. It was then left standing on ice for 1-2hrs before the mixture was 
centrifuged at 13,000g for 10 minutes and the supernatant discarded. The resulting 
pellet was washed three times with ice cold acetone and re-dissolved in 200µL of KOH 
then quantified for incorporated C14 isoleucine.  
2.6.3 SNAT2 Transport in Muscle 
To determine the effects of ageing and DHT treatment on SNAT2 amino acid uptake by 
the muscle fibre bundles, steps were repeated exactly as described before with the 
exception that the radioactive tracer was replaced by 68.3µM C14 α-
methylaminoisobutyric acid containing a radioactivity level of 0.8µCi/mL .  
(PerkinElmer, Buckinghamshire, UK) ran for 1hr as before. All samples probing for 
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SNAT2 transport were measure for raw AA uptake only, therefore there was no TCA 
precipitation step.  
2.6.4 Treatment of Chloroquine and Flutamide on Muscle 
All steps were followed as before. Groups were split into: control, chloroquine and 
DHT treated, flutamide, flutamide and DHT and DHT treatment alone. Muscles were 
pre-treated with 40µM chlorquine or 3µM flutamide  for one hour, then treated again 
with 40µM chloroquine  or 3µM flutamide  for the duration of the one-hour 
experiment within their respective groups. DHT was administered at the usual 
concentration of 2.17nM and ethanol was administered as vehicle control. Tissues 
were pulverised in liquid nitrogen and placed in NP40 buffer as usual. For amino acid 
uptake, the ground tissue lysate was tested directly. Liquid scintillation counting was 
used to quantify Ille-C14 and MeAIB-C14 quantities.  
2.6.5 SNAT2 and LAT2 transport in C2C12 Cells 
C2C12 radio-isotope treatments mirrored those of muscle drug interventions. 68.3µM 
C14 α-methylaminoisobutyric acid and 2mM C14 isoleucine were used mixed in cell 
media for the quantification of SNAT2 and LAT2 transport respectively. Radio-isotopes 
were only added at the start of 1hr experimental runs, they were not used in 
pretreatment.  
2.6.6 Scintillation Counting 
The amount of proteins in each lysate was first determined using the quick Bradford 
assay (Bradford, 1976) and the level of radioactivity in the mixture was determined 
using a liquid scintillation counter (Tri-Carb 2250 CA, Canberra-Packard). Ecoscint A 
(National Diagnostics, UK) was used as scintillation liquid, using 100µL of lysate per 
2mL of scintillation fluid. The scintillant and lysate solution was thoroughly mixed and 
allowed to stand overnight to quench. The next day the samples were examined using 
scintillation counter, with a count time of 2.5hrs per sample tube to allow for variance 
in C14 activity. Samples were kept away from light at all times. Each experiment was 
run a minimum of three times, using different cell colony each time.   
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Table 7: Summary of Drugs and Radio-Isotopes Used 
 
 
 
 
 
 
Ingredient Concentration Supplier Num. Supplier 
Absolute Ethanol 107.9µM NC9602322 Fisher Scientific, 
Loughborough, 
Leicestershire 
Dihydro-Testosterone 
(5α-Androstan-17β-ol-
3-one) 
4nM A8380-1G Sigma-Aldrich, 
Gillingham, Dorset 
Chloroquine 40µM C6628-25G Sigma-Aldrich, 
Gillingham, Dorset 
Flutamide 3µM F9397-1G Sigma-Aldrich, 
Gillingham, Dorset 
MeAIB-C14 68.3µM 
(0.8µCi/ml) 
NEC671050UC PerkinElmer, 
Buckinghamshire, 
UK 
Isoleucine-C14 2mM 
(3.46µCi/ml) 
NEC278E050UC PerkinElmer, 
Buckinghamshire, 
UK 
MeAIB 0.5,5,10mM M2383-250MG 
 
Sigma-Aldrich, 
Gillingham, Dorset 
SP600125 (JNK 
inhibitor) 
10µM S5567-10MG Sigma-Aldrich, 
Gillingham, Dorset 
Wartmannin  200nM S5567-10MG 
 
Sigma-Aldrich, 
Gillingham, Dorset 
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2.7 Expression Vector 
2.7.1 Plasmid Design and Sourcing 
SnapGene (GLS Biotech, USA) program was used to create plasmid sequence including 
a SNAT2 encoding insert. The pcDNA™3.1/CT-GFP (Genscript, USA) plasmid vector 
backbone was bought directly from Genescript using the SnapGene sequence. (see 
appendix A for vector structure) The plasmid contains a GFP tag useful for 
identification in fluorescence imaging and inserts conferring ampicillin and neomycin 
resistance.  
2.7.2 Plasmid Identification 
A restriction digest was performed on the expression vector to verify its identity 
following protocol from (Addgene, Cambridge USA). Reaction was prepared in 1.5mL 
Eppendorfs using 1 µg DNA, 1 µL each of restriction enzymes kpn1 (Sigma-Aldrich, UK 
R1258  and nhe1 (Sigma-Aldrich, UK R5634) 3 µL 10x Digestion Buffer 
and  25µL dH2O. Restriction digest was performed around the site of SNAT2 insert 
(omitting GFP tag) to assess for correct insert size. 
This was then ran on 1% agarose gel containing 0.3μg/mL EtBr at 120V in 1% TAE/EtBr 
and seperated using standard gel electrophoresis. This was then visualized using UV 
light imaging. An expected band at around 1001 base pairs was observed, showing the 
presence of SNAT2 and secondary band at 5138 base pairs was observed, accounting 
for plasmid backbone. 
A molecular sequence was provided by Genscript for conformation. A sample of the 
plasmid was sent to an independent analytical laboratory (Source Bioscience, 
Notthingham UK) to verify the molecular sequence.   
2.7.3 Plasmid Amplification 
The expression vector was amplified in DH5α Ecoli cells using protocol from (ABM, 
USA). Briefly, Ecoli cells were thawed on ice, 1μL of plasmid at a concentration of 10 
ng/µl was added per aliquot and left on ice for 30 minutes. These were then heat 
shocked for 45 seconds at 42°C, then placed back ice for 2 minutes. 150μL of sterile 
Lysogeny broth (see materials) was added and incubated for 1 hr at 37°C. Cells were 
plated and left overnight in incubator in LB broth at 37°C 95% O2/ 5%CO2 and sufficient 
humidity.  
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2.7.4 Plasmid Isolation 
Best colonies, as assessed by fluorescence imaging were chosen for vector purification. 
ABM Mini-Prep Kit (ABM, Vancuver Canada) was used for plasmid isolation Successful 
SNAT2 expressing cell colony was chosen and inoculated with LB broth. This was 
shaken at 37C overnight. 1.5 mL of cells were centrifuged at 13000 RPM for 1 minute. 
The supernatant was discarded. The cell pellet was resuspended in 100 uL of GTE 
buffer by vortex (see buffers 2.1.1). Solution was lysed by adding 200μl ABM Buffer 2 
and inverting tube 5 times, then keeping at room temperature for 1 min. 350μl of ABM 
Buffer 3 was then added and tube inverted repeatedly as before. This was spun at 
13,000 RPM for 1 minute. Supernatant was transferred to filtered spin column, 
centrifuged at 10,000 RPM for 2 min and resulting solution discarded. The filter was 
then washed with 750μl of wash solution, centrifuged and the resulting solution 
discarded once again. This wash step was repeated 2 more times. 50μl of elution 
buffer was added and the columns spun at 13,000 RPM for 2 min. 
The DNA was quantified using spectrophotometer at an absorbance of 260nm. Purified 
DNA was kept at -20°C for later use. 
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2.8 Fluorescence Imaging 
Tissue was dissected from mice of varying ages as outlined above. Isolated EDL and 
Soleus were put on ice to prevent protease degradation. These were placed on 
aluminium foil disc and dipped in isopentane which has been lowered in temperature 
by submersion in liquid nitrogen. In this way tissue damage from formation of ice 
crystals was minimised. Samples were kept at -80C until ready for use.  
Samples were mounted on stainless steel discs and kept vertical using pre cooled OTC 
mounting solution. Care was taken to ensure tissue did not thaw before being placed 
in the cooled cryostat. Cutting was performed at -20C. Sections were cut at a 
thickness of 10µm and placed onto gelatin coated glass slides and air dried.  
For fluorescent staining, slides were incubated in humidifier at all times to prevent 
evaporation.  Slides were incubated in 40% methanol for 30 seconds at 20C. Sections 
were then incubated in 4% paraformaldehyde for 10 minutes at 20C. These were then 
washed three times with PBS and blocked for 1hr with 5% goat or 1% horse serum to 
minimise nonspecific binding.  
Primary antibodies (SNAT2 H-60 Sc-166366 mouse monoclonal, Santa Cruz, USA) were 
incubated in 2% goat serum overnight at 4°C at dilution of 1:250. This was then 
washed three times with PBS under rocking for 10 minutes per washing. These were 
then incubated with secondary at a concentration of 2 µg/ml (A-11032 Alexa Flour 
594; anti-mouse; Thermo Fisher, USA) for 1hr at room temperature. 
These were then washed 3 times with PBS as before.  Fluoroshield DAPI containing 
mountant (Sigma-Aldrich, Gillingham, Dorset) was used to affix the slide covers. Slides 
were kept at 4C until ready to view.  
Slides were examined for fluorescence using Carl Zeiss Axio Imager using Axio Vision 
software. Alexa 594 channel was used to image SNAT2, while DAPI 354 channel was 
used to image DAPI. DAPI channel was exposed for 20ms while SNAT2 was exposed for 
500ms. Resulting images were not altered and ImageJ (Scion/NIH) was used to 
quantify signal at the plasma membrane.  
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2.9 Immunoprecipitation 
2.9.1 Setup 
Upon delivery, the beads were incubated with 1ml of PBS to allow beads to swell up. 
These were centrifuged and the supernatant discarded. 1ml of PBS/0.1% BSA was 
added as blocking agent, mixed for 1h on a rotator and then rinsed twice with PBS. 
1mL aliquots of bead slurry were then stored at 4-8°C until ready for use. 
2.9.2 Immunoprecipitation 
Immunoprecipitation was used following Abcam IP protocol using Protein A Sepharose 
beads. The beads were first crosslinked with SNAT2 antibody. First, 100µL of slurry 
from stock bottle was transferred to a microcentrifuge tube. To this, the SNAT2 
polyclonal (Santa Cruz Biotechnology, Santa Cruz, Ca, USA) antibody was added at a 
final concentration of 2µG/100µL. This was then incubated on a rotator at 4°C for 4h. 
This was centrifuged for 5min at 3000rpm then washed with PBS buffer twice. 30uL of 
tissue lysate in NP40 buffer was transferred into the microcentrifuge per 100uL pre 
made bead slurry. This was incubated overnight at 4°C on rotator. The beads were 
then centrifuged as before and washed using wash buffer three times.  
2.9.3 Elution 
The beads were eluted using a SDS elution method. They were heated with 50uL of 
SDS buffer for 10min at 50C. The beads were then placed in 750uL centrifugal 
microfilters and spun at 10,000g for 5 minutes and supernatant kept. For the second 
elution, 50uL of SDS buffer was added with addition of 100mM DTT. The samples were 
boiled for 5min and centrifuged as above. Both elutes were kept and analysed by 
Western Blotting.  
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2.10 Statistical Analysis 
Control and individual treatment/intervention groups were organised as nominal data, 
while their corresponding respective quantifications were organised on an interval 
scale. 95% Confidence interval was used and a minimum n value of 3 for any statistical 
analysis. Significance was defined as p<0.05.   
Analysis was performed using SPSS software version 20. Analysis of variance was 
performed on all data sets (ANOVA) followed by Bonferroni post hoc test. Type of 
ANOVA used varied on each dataset. Two-way ANOVA was used for studying 
significance with two independent variables such as testing of effects of age and 
muscle type on AA transporter expression and transport. (chapters 3 and 4) One-way 
ANOVA was used for datasets containing only one independent variable, such as 
myoblast and myotube experiments in chapters 4 and 5. Type of variance tests used 
are specified in figure legends.  
2.11 Image Creation  
Image J (scion/NIH) was used for Western Blot and fluorescence image quantification. 
Background was always accounted for by reducing intensity of entire blot by the 
intensity of a clear portion of the blot. For Western Blot analysis the intensity of the 
bands of interest were normalised to the corresponding actin intensity and the data 
presented are the mean of the blots performed.  
Fluorescence images were quantified for plasma membrane intensity by a method 
proven in plasma membrane quantification of human embryonic kidney cells (Leterrier 
et al., 2004). This was done by manually drawing around the outer ages of the cells, 
selecting the area within. This intensity was calculated as whole cell intensity. Erode 
command was used to subtract selection area away from edges by 5 pixels. This was 
calculated to be cytoplasmic intensity. Whole cell – cytoplasmic intensity was 
determined to calculate plasma membrane intensity. This was done individually to 
eliminate overlap between cells.  
All Illustrative images were produced using Adobe Flash CS5.  
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2.12 Experimental Limitations 
Various experimental limitations were identified during these experiments. These 
include but are not limited to: 
 
• Relatively small sample sizes of animals due to high cost and availability of aged 
animals.  
• Experimental runs of DHT uptake on skeletal muscle was performed at 22°C not 
physiological temperature.  
• 107.9µM of ethanol had to be included in all DHT and control experiments (due 
to poor solubility of DHT). 
• Uptake quantification was observable only at the endpoint of experiments.  
• Transfection rate of SNAT2 plasmid was 10-20%. 
• Limited choice of inhibitors and agonists due to high cost of radioactive 
isotopes.  
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Chapter 3: Effects of ageing on mice skeletal muscle 
3.1 Aim 
3.2 Results 
3.2.1  Effect of ageing on muscle weight. 
3.2.2 Effect of age on SNAT2 and LAT2 transporter protein expression.  
3.2.3 Effect of ageing on amino acid transport into muscle 
3.2.4 Effect of ageing on incorporation of amino acids into muscle protein.  
3.2.5    Effect of ageing on SNAT2 and LAT2 mRNA expression 
3.3 Discussion 
3.1  Aim 
The aim of chapter 3 is to determine the effects of ageing on mice skeletal muscle. The 
parameters investigated were muscle weight, SNAT2/LAT2 expression and transport, 
and protein synthesis. This data allowed for the quantification of the effect of ageing 
on mice and would serve as a baseline for further experiments. 
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3.2 Results 
3.2.1  Effect of ageing on muscle weight. 
Firstly, we investigated the effects of ageing on skeletal muscle mass alone. Initially 
three age groups were tested: 100 day old mice representing post pubescent young 
mice, 300 day old “mature” mice representing fully mature mice, and mice over 700 
days old, representing an elderly group. These mice ages were chosen based on 
previous work in mice development and ageing (Banerjee et al., 2014). The first 
experiment recorded the total weight of the isolated extensor digitorum longus (EDL) 
and soleus (SOL) muscles in each age group. Total muscle mass was chosen because it 
is the predominant determinant of force production in mice (Bonetto et al., 2015), and a 
reduction of total muscle mass is the primary observation in sarcopenia.  Fig. 3.1A 
shows that ageing led to a marked decline in the total weight of the EDL and SOL 
muscle.  EDL weight fell by ~50% with an approximate ~25% fall for SOL.  
An accumulation of body fat relative to muscle mass is known as sarcopenic obesity 
(Lee and Park, 2015) which correlates with reduced prognosis and increased chance of 
disability when compared with muscle loss alone (Zoico et al., 2004).  Sarcopenic obesity 
was assessed from the ratio of the muscle weight to the whole weight of the animal to 
account for increase in fat mass proportional to lean mass (Fig 3.1B). In figure 3.1B the 
weight of the muscle is expressed as a percentage of total body weight. The weight of 
the muscle dropped from ~1.4% of body weight in young mice to between 0.4% and 
0.6% body weight for the EDL, and soleus muscles in elderly mice, respectively. The 
elderly mice therefore showed a marked decline in proportional lean mass when 
compared to young and mature mice. This was effect was greater in fast twitch EDL 
muscle. 
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Figure 3.1A.  Effect of age on muscle weight in mice. Fast twitch extensor digitorum 
longus (EDL) and slow twitch soleus (SOL) muscles were isolated from mice at the indicated 
ages and weighed.  Young mice were ~100 day old, mature mice ~300 days old and elderly 
mice were over 700 days old.  EDL white bars SOL black bars). No significant difference was 
found between muscle weights of young and mature cohorts (* to * p>0.05) Elderly muscle 
weights were significantly lower in both EDL and SOL groups as compared to both young and 
mature mice (+ to * p<0.01 and # to * p<0.05). 2-Way ANOVA used, n=12.  
 
 
Figure 3.1B Effect of age on sarcopenic obesity in mice. Fast twitch extensor digitorum 
longus (EDL) and slow twitch soleus (SOL) muscles were isolated from mice at the indicated 
ages.  Young mice were ~100 day old, mature mice ~300 days old and elderly mice were over 
700 days old.  EDL white bars SOL black bars.  The weight of each muscle was calculated as a 
percentage of the total weight of the animal. each respective age group showed significant 
difference between age groups (difference between # + and *  p<0.05). There was no 
significant difference between muscle types (**, ##, ++ p>0.05). 2-Way ANOVA used, n=12. 
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Interestingly, there was no statistical difference in terms of total muscle weight 
between young and mature mice.  This is in line with observable onset of sarcopenic 
muscle loss in humans and rhesus monkeys (Colman et al., 2005). However, figure 3.1B 
shows that the percentage of muscle weight relative to total body weight decreased 
with age in a linear fashion in both fast extensor EDL and slow SOL with the young, 
mature and elderly groups all showing statistically significant differences (p<0.05) 
between each other. This is likely explained by a gradual accumulation of adipose 
tissue in our mice cohorts and is evidence of the well documented phenomenon of 
sarcopenic obesity (Lee et al., 2016b). The increase in adipose tissue is not a marker of 
sarcopenia, but rather a contributing factor in its onset, which is evident as muscle 
dysfunction and loss at the terminal stages of the mice lifespan. It is worth noting that 
weights of SOL are more conserved than EDL in elderly mice. This is evidence of SOL 
being more resistant of the effects of ageing then EDL, a phenomenon that has been 
observed before in other mammalian models (Demontis et al., 2013). 
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3.2.2 Effect of age on SNAT2 and LAT2 transporter protein expression.   
Muscle mass is maintained by protein synthesis which in turn requires amino acid 
transport into muscle cells by amino acid transporters.  An age dependent reduction in 
the expression or function of amino acid transporters such as SNAT2 and LAT2 could 
lead to a decline in muscle mass.  The next experiment therefore analysed the 
expression of SNAT2 and LAT2 in mice in different age groups. Tissues were extracted 
and lysed using NP40 buffer and probed by western blot. The figures 3.2A and 3.2B 
show representative western blots while bar graphs show average expression in three 
mice calculated from densitometric analysis of blots. The results in figure 3.2 show, 
that when young mice were compared to elderly mice there was a decrease in the 
expression SNAT2 (Figure 3.2A) and LAT2 (Figure 3.2B) in both fibre types and in each 
case the decrease in SNAT2 (~31%) was slightly greater than that of LAT2 (~25%). In 
contrast the mature mice showed an increase in SNAT2 and LAT2 expression when 
compared to young or elderly mice.  
This increase between young and mature mice may be due to mice of 100 days of age 
having not yet attained full maturity. As they undergo puberty and experience high 
levels of testosterone (and by proxy dihydrotestosterone) they will rapidly gain muscle 
mass, especially fast twitch muscle with increased physical activity. The 100 day old 
mice, having only reached their peak testosterone production, have not had the same 
length of time to produce the same quantity of amino acid transporters compared to 
the mature groups, which have been exposed to higher levels of anabolic stimulus for 
longer. Therefore, to rule out this anomaly we decided to compare the 300 day old 
mature mice to the 700+ day elderly mice for the rest of the experiments (Banerjee et 
al., 2014). 
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Figure 3.2A Effect of ageing on SNAT2 expression. Fast twitch extensor digitorum longus 
(EDL) and slow twitch soleus (SOL) muscles were isolated from young mice at ~100 days old, 
mature mice ~300 days old and elderly mice at over 700 days old. The figure shows a 
representative western blot while the bar graphs shows average expression calculated from 
densitometric analysis of blots from separate mice with SNAT2 expression normalised for actin 
used as a loading control. EDL are represented by white bars and SOL muscle by black bars. * 
and unmarked groups are statistically indifferent to each other(p>0.05). Difference between 
mature EDL (#) to young, and elderly EDL (unmarked) is statistically significant (p<0.05) Elderly 
SOL (+) is significantly smaller to young or mature SOL (*)(p<0.05). 2-way ANOVA used, n=4.  
 
 
 
 
 
 
 
0
0.5
1
1.5
2
2.5
3
3.5
4
YOUNG YOUNG MATURE MATURE ELDERLY ELDERLY
SN
A
T2
/ 
A
c 
ti
n
SNAT2 Protein Expression
*
*
+
#
61 
 
 
 
 
 
 
 
 
 
Figure 3.2B Effect of ageing on LAT2 expression. Fast twitch extensor digitorum longus 
(EDL) and slow twitch soleus (SOL) muscles were isolated from young mice at ~100 days old, 
mature mice at ~300 days old and elderly mice at over 700 days old. The figure shows a 
representative western blot while the bar graphs shows average expression calculated from 
densitometric analysis of blots from separate mice with LAT2 expression normalised for actin 
used as a loading control. EDL are represented by white bars and SOL muscle by black bars. All 
unmarked groups are statistically indifferent to each other(p>0.05). Difference between 
mature EDL (unmarked) to elderly EDL (+) is statistically significant (p<0.05) Elderly SOL (#) is 
also significantly smaller to both young or mature SOL (unmarked)(p<0.05). 2-Way ANOVA 
used with n=4.  
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3.2.3 Effect of ageing on amino acid transport into muscle 
A marked reduction was evident in SNAT2 and LAT2 protein levels when skeletal 
muscle from mature mice was compared to that of elderly mice as shown in section 
3.2. The next step was to determine whether this reduction in expression would 
translate to reduced amino acid transport into the muscle. In the next experiment the 
uptake of amino acids into the muscle tissue was assessed by incubating muscle fibres 
with C14 conjugated MeAIB. MeAIB is an N-methylated amino acid analogue that  is 
transported exclusively through the SNAT family of amino acid transporters, in 
particular SNAT2 (Zhang and Grewer, 2007). Importantly, MeAIB is not a substrate for 
LAT2 (Yao et al., 2000). Therefore, measuring C14MeAIB uptake into muscle can be 
used to accurately quantify changes in transport through SNAT2.  
Transport through LAT2 was assessed using C14-Isoleucine, a branched chain amino 
acid conjugated to the C14 radioisotope. Isoleucine is one of the preferred substrates 
for LAT2, (Lingrel and Kuntzweiler, 1994) and importantly, unlike leucine it does not 
stimulate protein synthesis (Anthony et al., 2000). Fast and slow-twitch muscle fibre 
bundles were incubated in Ringer’s solution (See Buffers 2.1.1) containing C14MeAIB or 
C14Isoleucine for 1hr, the fibre bundles were washed in PBS and snap frozen in liquid 
nitrogen, pulverised and lysed with NP40 buffer. The mixture was centrifuged and the 
supernatant was collected for scintillation counting to assess amino acid transport as 
described in methods.   
Figure 3.3A shows uptake of MeAIB into muscle fibres over one hour as a measure of 
transport through SNAT2 and shows that SNAT2 transport was significantly reduced in 
elderly (>700 day) muscle compared to mature (300 days).  For fast twitch EDL muscle 
and slow twitch SOL muscle SNAT2 transport fell by nearly half in the elderly cohorts. 
The SOL group showed higher transport in both the mature and elderly animals, 
compared to the respective EDL groups. When the extent of loss from mature to 
elderly groups were compared statistically there was no significant difference between 
muscle types, but a trend toward higher remaining function in SOL was observed 
(p=0.119).   
63 
 
 
Similarly Figure 3.3B shows total transport of C14Isoleucine into the cell. We see the 
same pattern as before. SOL groups show approximately a third higher uptake than 
EDL in both age groups. There is a significant (p<0.05) decrease in both EDL and SOL 
with ageing as seen before in C14MeAIB uptake.  
 
 
 
 
 
 
Figure 3.3A Effect of ageing on SNAT2-mediated amino acid transport in muscle 
fibres. Fast and slow-twitch muscle fibre bundles of ~300 day old (mature) and 700+day old 
(elderly) CD-1 mice were incubated Ringer’s solution containing C14MeAIB for 1hr, the fibre 
bundles were washed in PBS and snap frozen in liquid nitrogen, pulverised and lysed with 
NP40 buffer and scintillation counting used to quantify. The white bars represent fast twitch 
EDL fibres and the black bars represent slow twitch SOL. All groups were statistically different 
from each other (p<0.05). Mature EDL (unmarked) showed a significant difference to elderly 
EDL (*). Likewise, the elderly SOL (#) showed a significant decline in transport to mature SOL 
(+) 2-way ANOVA used, n=3.  
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Figure 3.3B Effect of ageing on amino acid LAT2-mediated transport in muscle fibres. 
Fast and slow-twitch muscle fibre bundles of ~300 day old (mature) and 700+day old (elderly) 
CD-1 mice were incubated Ringer’s solution containing C14Isoleucine for 1hr, the fibre bundles 
were washed in PBS and snap frozen in liquid nitrogen, pulverised and lysed with NP40 buffer 
and scintillation counting used to quantify. The white bars represent fast twitch EDL fibres and 
the black bars represent slow twitch SOL. Unmarked groups (mature EDL and elderly SOL) were 
statistically indifferent (p>0.05). Elderly EDL (*) showed a significant reduction as compared to 
mature EDL (unmarked) (p<0.05). Likewise, the elderly SOL (unmarked) showed a significant 
decline in transport to mature SOL (+) 2-way ANOVA used, n=3. 
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3.2.4 The effect of ageing on incorporation of amino acids into protein.  
The experiments above (3.2A-B and 3.3A-B) have shown that there was reduced 
expression of SNAT2 and LAT2 transporters in elderly muscle and this correlated with 
reduced transport of amino acids through these transporters into muscle fibres ‘in 
vitro’.  The next experiment determined if incorporation of amino acids into protein 
was also compromised with age. Fast and slow-twitch muscle fibre bundles were 
incubated Ringer’s solution containing C14 Isoleucine for 1hr, the fibre bundles were 
washed in PBS and snap frozen in liquid nitrogen, pulverised and lysed with NP40 
buffer as before. An additional step was incorporated, the mixture was centrifuged and 
the supernatant was mixed with ice-cold TCA and acetone to precipitate protein. 
Precipitates dissolved in KOH were analysed by for incorporation of amino acids by 
scintillation counting. 
The results in figure 3.4 show ageing led to a decrease in protein synthesis in both 
muscle fibre types when >700 day elderly mice were compared to mature 300 day old 
mice.  The graph also shows that in each case protein synthesis was significantly higher 
in the slow-twitch than in the corresponding fast-twitch fibres. The loss of amino acid 
incorporation was greater in the fast-twitch elderly fibres which showed a reduction of 
47.33% (±4.92%) compared to mature muscle. The slow muscle fibres on the other 
hand, showed a reduction of only 30.95% (±5.36%) in protein synthesis compared to 
mature controls. These results further reinforced the notion that fast twitch muscle is 
affected to a greater extent than slow twitch muscle during ageing. Slow twitch muscle 
appears more resistant to ageing, by both retaining greater total muscle weight and 
retaining function of amino acid transporters. The same trend is shown in the ability of 
older muscle fibres to incorporate amino acids into protein as shown in fig 3.4.  
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Figure 3.4 Effect of ageing on amino acid incorporation into muscle protein.  Fast and 
slow-twitch muscle fibre bundles were incubated Ringer’s solution containing C14Isoleucine for 
1hr, the fibre bundles were washed in PBS and snap frozen in liquid nitrogen, pulverised and 
lysed with NP40 buffer. The mixture was centrifuged and the supernatant was precipitated in 
TCA and dissolved in KOH. Scintillation counting was used to assess amino acid incorporation 
into protein. The white bars represent fast twitch EDL fibres and the black bars represent slow 
twitch soleus. Mature mice were ~300 days old and elderly mice were over 700 days old. 
Elderly EDL (*) showed a significant reduction to mature EDL (unmarked) (p<0.05). Likewise, 
elderly SOL (unmarked) showed a significant reduction from mature SOL (+)(p<0.05). 2-way 
ANOVA used, n=4. 
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3.2.5 Effect of ageing on SNAT2 and LAT2 mRNA expression 
To determine the mechanism underlying this age-dependent decline in SNAT2 protein 
expression, the effects of age on SNAT2 and LAT2 expression at the mRNA level was 
investigated. Real Time PCR was performed at 35 cycles for both transporters, using 
S29 as the house keeper gene. ΔΔCT values are presented as relative mRNA expression 
to more easily compare proportional levels of expression.   
There was a significant (p<0.05) decline in SNAT2 mRNA expression with ageing as 
seen in Fig 3.5B. This reduction in mRNA expression likely contributes to the decline in 
protein seen with ageing in SNAT2 seen in 3.2A. Fast twitch EDL fibres show that 
58.40±3.77% of mRNA expression remains in elderly muscle, while for slow twitch SOL 
this value is 52.94±2.11%. 
As the results displayed in figure 3.5A shows, age had no statistically significant effect 
on LAT2 mRNA expression. However, there was a trend noticed toward a reduction 
with ageing which did not reach significance level (p=0.127). Fast twitch elderly muscle 
shows 76.42±4.36% expression, while slow twitch elderly muscle retains 83.59±3.18% 
expression. 
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Figure 3.5A.  Effect of ageing on SNAT2 mRNA expression.  Total RNA was extracted 
from fast-twitch and slow-twitch muscle fibre bundles using TRIzol® reagent. 1µg of RNA was 
reverse transcribed and expression of SNAT2 determined after 35 cycles of amplification at 
55°C.  The white bars represent fast twitch EDL fibres and the black bars represent slow twitch 
soleus. Mature mice were ~300 days old and elderly mice were over 700 days old. EDL elderly 
group (*) showed a statistically significant reduction from EDL of mature group 
(unmarked)(p<0.05). Likewise SOL elderly (+) mice showed a significant reduction (p<0.05) 
from SOL mature cohort (unmarked). 2-way ANOVA used, n=4. 
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Figure 3.5B.  Effect of ageing on LAT2 mRNA expression.  Total RNA was extracted from 
fast-twitch and slow-twitch muscle fibre bundles using TRIzol® reagent. 1µg of RNA was 
reverse transcribed and expression of SNAT2 determined after 35 cycles of amplification at 
55°C.  The white bars represent fast twitch EDL fibres and the black bars represent slow twitch 
soleus. Mature mice were ~300 days old and elderly mice were over 700 days old. EDL elderly 
group (*) did not show a statistically significant reduction from EDL of mature group 
(unmarked)(p=0.119). Likewise SOL elderly (+) failed to show a statistically significant 
reduction (p=0.087) from SOL mature cohort (unmarked). A trend toward reduction was 
observed in both groups however. 2-way ANOVA used, n=4. 
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3.3 Discussion  
In this chapter, we have shown that ageing has significant and quantifiably detrimental 
effects on mice skeletal muscle.  We have shown that in the aged group, SNAT2 and 
LAT2 protein levels diminish which can be partly attributed to reductions in mRNA 
expression shown in Figures 3.5A-B. There was a trend towards reduction of mRNA 
levels in both SNAT2 and LAT2 with ageing, however only SNAT2 are found to be 
statistically significant. Note that this corresponds to the reductions in AA transporter 
protein expression seen in 3.2A and 3.2B. 
These results are mirrored by the uptake studies showing a similar degree of reduction 
in AA transport, suggesting that the phenomenon involved is the reduction in the 
quantity of functional SNAT2 and LAT2 transporters rather than altered efficacy of 
transporter activity. It has been shown that the Km of SNAT2 does not change in 
response to hormonal stimulation, amino acid deprivation, or ageing (Franchi-Gazzola 
et al., 2006, Kashiwagi et al., 2009).  
We have also established that these changes seem to be more profound in the fast 
twitch fibres then the slow twitch fibres as evidence from the uptake data in fig 3.3A-B 
and protein incorporation (fig3.4). The predominantly slow twitch fibres of the slow 
twitch soleus appear to be more resistant to the effects of ageing. This finding is in line 
with human data showing a trend toward a greater proportion of fibres exhibiting a 
slow twitch phenotype in elderly patients as compared to young. Elderly patients are 
found to be expressing myosin heavy chain type I (MHC-I is characteristic of slow 
twitch fibre) to a much greater extent than young subjects as well as showing evidence 
of old fibres switching from fast to slow twitch (Andersen, 2003). It is because of this 
rapid and profound switching that it may be possible to use fibre typing markers to aid 
the diagnosis of sarcopenia. The slow MLC2 isoform for instance, has been proposed as 
a possible biomarker indicative of sarcopenia onset (Gannon et al., 2009). 
The sharp decline in SNAT2 or LAT2 levels during ageing could also serve as a 
diagnostic marker, due to the direct link of these AA transporters with muscle protein 
synthesis and function.  
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We have identified that SNAT2 and LAT2 are in fact greatly reduced in ageing at a 
protein level. This is likely manifested as a decrease in functional transporters available 
for utilisation of AA transport into elderly muscle cells.  
It is still unclear why this age-related decline occurs.  In the case of SNAT2, we have 
found a significant decrease in the mRNA of the transporter in elderly mice. This can at 
least partially explain the reduction in total protein expression of transporter levels 
seen in the elderly cells. However, in the case of LAT2 there was no statistically 
significant reduction at the mRNA level with age, although there was a clear trend 
observed toward reduction in both fibre types. Like in many biological processes, it is 
likely that the cause behind impaired function of these transporters is multifactorial.  
These findings help elucidate an underlying mechanism of sarcopenic muscle 
dysfunction. As patients lose fast twitch fibres with age, they lack the power to initiate 
coordinated movements leading to increased risk of falls and greater disability, a 
hallmark of sarcopenia. To date there is little known about the role of SNAT2 and LAT2 
in ageing, but based on the findings herein, it is likely that these amino acid 
transporters play a significant role.  
There is more work needed to find the underlying causes of these changes in AA 
transport and to assess whether reversing these processes is a viable possibility. We 
theorise that the determining factor for AA transporter recruitment is a baseline 
anabolic signal mediated by DHT, the active metabolite of testosterone, that causes 
the movement of SNAT2 and LAT2 from an intercellular pool and determines the 
availability of said transporters on the plasma membrane. This theory will be tested in 
chapter 4.  
Limitations of this chapter include the small sizes of animal cohorts, which were due to 
the high costs of aged animals. The studies were performed only on female CD-1 mice, 
and only in 1hr durations, with detection only possible at the end of experiments 
instead of throughout. Mice diet was kept consistent, but mice were not starved prior 
to sacrifice and dissection.  
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Table 8.3 Summary of Chapter 3 
Table 3.3 Summary of results derived from experiments on effects of ageing alone. Note that 
these differences are approximations for comparative purposes. We see a significant decline in 
all parameters tested aside from LAT2 mRNA expression, difference in which did not reach 
statistical significance. 
 
 
 
 
 
Baseline Ageing MATURE FAST 
          
MATURE SLOW ELDERLY FAST ELDERLY SLOW 
SNAT2 Protein     ••    ••••    •    ••• 
LAT2 Protein     ••••    ••••    •    •• 
SNAT2 mRNA    ••    ••••    •    •• 
LAT2 mRNA    •••    ••    •••    •• 
C14MeAIB 
Transport    •••    ••••    •    •• 
C14Isoleucine 
Transport    ••    •••    •    •• 
Protein 
Synthesis    ••    •••    •    •• 
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Chapter 4: Effects of DHT on muscle ageing 
4.1 Aim 
4.2 Results 
4.2.1  Effects of DHT on expression of SNAT2 and LAT2 in aged muscle. 
4.2.2 Effects of DHT on transport of amino acids by SNAT2 and LAT2 in aged 
muscle. 
4.2.3 Effects of DHT on incorporation of amino acids into protein in aged 
muscle. 
4.2.4 Effects of chloroquine on DHT-induced increases in amino acid 
transport by aged muscle. 
4.2.5    Effects of low temperature on DHT-induced increases in amino acid 
transport by aged muscle. 
4.2.6    Effect of ageing and DHT on cellular location of SNAT2 in muscle fibres.  
4.2.7  Effect of DHT on amino acid transport in C2C12 myoblasts and 
myotubes. 
4.2.7    Effects of DHT and chloroquine on cellular location of SNAT2 in muscle 
fibres. 
 ________________________________________________________________ 
4.3 Discussion 
4.1 Aim 
To determine effect of acute DHT treatment on mature and elderly mice skeletal 
muscle. To assess whether age related dysfunction in AA transport and protein 
synthesis can be reversed with DHT treatment.  
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4.2 Results 
4.2.1 Effects of DHT on expression of SNAT2 and LAT2 in aged muscle. 
The ability of DHT to affect the expression and/or function of SNAT2 and LAT2 was 
tested by incubating muscle fibres with DHT for one hour. This time course was chosen 
to rule out classical genomic effects. Physiological concentrations of DHT were used at 
equivalent of 600pg/nL (normal biological range of 240-650 pg/nL) (Weng et al., 2010).  
Expression of SNAT2 and LAT2 protein were assessed by immune blotting of fibres 
isolated from ~100 day old mice representing young mice, ~300 day old representing 
fully mature mice, and elderly mice over 700 days old. 
The results in chapter 3 (figures 3.2A-B) showed that expression of SNAT2 and LAT2 
was reduced in muscle fibres isolated from elderly mice compared to young and 
mature mice.  Figures 4.1A and 4.1B show that this decline in amino acid transporters 
was reversed when same age mouse fibres were incubated in DHT for one hour. The 
representative western blots show that muscle fibres of elderly mice treated with DHT 
express statistically equal levels (p<0.05) of SNAT2 protein compared to DHT treated 
mature mice. This is true in both the SOL and EDL muscles.  
In the study of LAT2 protein expression (fig 4.1B) the data shows the average of three 
western blots normalised to the actin loading control. Levels of LAT2 in EDL fibres are 
no different in DHT treated elderly muscle than in DHT treated mature muscle. The 
ability of DHT to rescue LAT2 expression in elderly slow twitch SOL was less 
pronounced, evidenced by the LAT2 elderly SOL showing lower expression than the 
mature group (p<0.05). This data potentially shows preliminary evidence of the EDL 
exhibiting a greater response to the DHT treatment than SOL.    
As before the young ~100 day old mice are not discussed here due to the high 
variability of results. Interestingly the fast twitch EDL in young mice is not receptive to 
DHT treatment, showing expression of both SNAT2 and LAT2 below that of the other 
ae groups (p<0.05). However, the slow twitch SOL of young mice is responsive to DHT 
treatment, showing the same levels as the other age groups in LAT2 expression. 
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Further study is needed to elucidate the link in early development and AA transporter 
expression. 
 
 
  
Figure 4.1A Effect of DHT in SNAT2 protein expression in muscle fibres ‘in vitro’. Fast 
twitch extensor digitorum longus (EDL) and slow twitch soleus (SOL) muscles were isolated 
from:  young mice (~100 day old), mature mice (~300 days old) and elderly mice (over 700 days 
old).  Muscles were incubated in Ringers solution with or without DHT for one hour at 370C.  
Fibres were extracted using NP40 buffer and expression of SNAT2 analysed by western 
blotting.  The figure shows a representative western blot while the bar graphs shows average 
expression calculated from densitometric analysis of blots from three mice with SNAT2 
expression normalised for actin used as a loading control actin.  EDL is represented by white 
bars, while  SOL is represented by black bars.  In fast twitch EDL, the mature (#) and elderly (#) 
groups were statistically indifferent (p>0.05), while the young EDL (*) showed lower expression 
(p<0.05). In the slow twitch SOL, mature (unmarked) and elderly (unmarked) groups were 
similar (p=0.069), while young (+) was lower to mature (p<0.05). Two-way ANOVA used, n=3. 
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Figure 4.1B Effect of DHT in LAT2 protein expression in muscle fibres ‘in vitro’.   
Fast twitch extensor digitorum longus (EDL) and slow twitch soleus (SOL) muscles were 
isolated from:  young mice (~100 day old), mature mice (~300 days old) and elderly mice (over 
700 days old).  Muscles were incubated in Ringers solution with or without DHT for one hour at 
370C.  Fibres were extracted using NP40 buffer and expression of LAT2 analysed by western 
blotting.  The figure shows a representative western blot while the bar graphs shows average 
expression calculated from densitometric analysis of blots from three mice with LAT2 
expression normalised for actin used as a loading control actin.  EDL is represented by white 
bars, while SOL is represented by black bars. In fast twitch EDL group, mature (unmarked) and 
elderly (unmarked groups were statistically the same (p>0.05), whilst the young (*) group 
showed significantly lower expression (p<0.05). In the slow SOL group, the young (unmarked) 
and mature (unmarked) showed no difference (p>0.05), whilst the elderly SOL (+) showed 
statistically lower LAT2 expression with DHT treatment (p<0.05) Two-way ANOVA used, n=3. 
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4.2.2 Effects of DHT on transport of amino acids by SNAT2 and LAT2 in aged muscle. 
The next experiments studied the effect of DHT on uptake of C14 conjugated MeAIB 
and Isoleucine to assess if DHT treatment increased transport through SNAT2 and LAT2 
transporters. Figure 4.2A shows uptake of C14 conjugated MeAIB as an assay for SNAT2 
activity and compares fibres from mature mice (~300 day old) with fibres from elderly 
mice (over 700 days old). Young mice (~100day old) were not studied from this point 
forward. In line with the increased levels of SNAT2 protein detected by western blot of 
elderly fibres incubated with DHT (figure 4.1A), there was evidence for increase in 
uptake of MeAIB in response to DHT in the elderly cohorts.  There was also a trend for 
increased uptake in mature fibres, but this change was not significant (p>0.05).   
DHT treatment increased uptake of MeAIB in the elderly mice, and this was most 
obvious for fast twitch EDL fibres. The DHT treatment rescued the elderly EDL fibres to 
a level that showed no statistical difference from that of mature treated EDL fibres 
(p>0.05). The percentage increase in transport presented in figure 4.2A shows a 46% 
increase for elderly EDL fibres with DHT, and only 10% for mature fibres.  Slow muscle 
fibres showed less marked responses to DHT, increasing 21% in elderly and 8% in 
mature mice (Fig 4.2B).   
The experiment was repeated using C14Isoleucine to measure LAT2 transport in figure 
4.2C.  As before, DHT increased uptake of the radioisotope, and this was most 
profound in the elderly EDL. As with MeAIB uptake, the fast EDL of the elderly group 
showed no difference to the fast EDL of mature controls (p>0.05). This again suggested 
that the age-related reduction in LAT2 transport was reversed with DHT treatment. 
The % increase in transport from data in fig 4.2C shows a 72% increase for elderly EDL 
fibres with treatment, and only 9% for mature fibres.  Slow muscle fibres (fig 4.2D) 
showed less marked responses to DHT of 17% in elderly and 0.2% in mature.  
As before, these experiments offer strong evidence that the response to DHT is far 
greater in the elderly muscle than mature. Also, fast EDL is more responsive to 
treatment than SOL, shown by the percentage increase figures from the data.  
78 
 
 
Figure 4.2A.  Effect of DHT on C14MeAIB transport in EDL muscle fibres ‘in vitro’.   Fast 
twitch muscle fibre bundles were incubated Ringer’s solution containing DHT and C14 MeAIB 
for 1hr, the fibre bundles were washed in PBS and snap frozen in liquid nitrogen, pulverised 
and lysed with NP40 buffer. The mixture was centrifuged and the supernatant was collected 
for scintillation counting to assess amino acid transport. Mature mice were ~300 days old and 
elderly mice were over 700 days old. Only statistical difference was found in elderly controls 
(*) which were significantly reduced (p<0.05) compared to mature control, mature DHT and 
elderly DHT (all unmarked). 1-way ANOVA used, n=4. 
Figure 4.2B.  Effect of DHT on C14MeAIB transport in SOL muscle fibres ‘in vitro’.   
Slow twitch muscle fibre bundles were incubated Ringer’s solution containing DHT and C14 
MeAIB for 1hr, the fibre bundles were washed in PBS and snap frozen in liquid nitrogen, 
pulverised and lysed with NP40 buffer. The mixture was centrifuged and the supernatant was 
collected for scintillation counting to assess amino acid transport. Mature mice were ~300 
days old and elderly mice were over 700 days old. Although there was a trend seen toward 
increase in both groups, DHT treatment did not result in statistically significant increases 
(p<0.05) in  either mature or elderly SOL. 1-way ANOVA used, n=4.  
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Figure 4.2A.  Effect of DHT on C14Isoleucine transport in EDL muscle fibres ‘in vitro’.   
Fast twitch muscle fibre bundles were incubated Ringer’s solution containing DHT and C14 
MeAIB for 1hr, the fibre bundles were washed in PBS and snap frozen in liquid nitrogen, 
pulverised and lysed with NP40 buffer. The mixture was centrifuged and the supernatant was 
collected for scintillation counting to assess amino acid transport. Mature mice were ~300 
days old and elderly mice were over 700 days old. Only statistical difference was found in 
elderly controls (*) which were significantly reduced (p<0.05) compared to mature control, 
mature DHT and elderly DHT (all unmarked). 1-way ANOVA used, n=4. 
Figure 4.2B.  Effect of DHT on C14Isoleucine transport in SOL muscle fibres ‘in vitro’.   
Slow twitch muscle fibre bundles were incubated Ringer’s solution containing DHT and C14 
MeAIB for 1hr, the fibre bundles were washed in PBS and snap frozen in liquid nitrogen, 
pulverised and lysed with NP40 buffer. The mixture was centrifuged and the supernatant was 
collected for scintillation counting to assess amino acid transport. Mature mice were ~300 
days old and elderly mice were over 700 days old.  There was a trend seen toward increase in 
elderly group (*), but DHT treatment did not result in statistically significant increases (p<0.05) 
in  either the mature or elderly SOL. 1-way ANOVA used, n=4.  
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4.2.3 Effects of DHT on incorporation of amino acids into protein in aged muscle. 
The work in chapter 3 showed that incorporation of amino acids into protein was 
reduced in muscle fibres from elderly mice compared to those of mature aged mice 
(figure 3.4).  The possibility that the increased activity of SNAT2 and LAT2 might 
increase amino acid incorporation into muscle protein was tested by analysing 
incorporation of radioactive isoleucine into TCA-insoluble material.  Figure 4.3A shows 
that DHT increased incorporation of radioactive isoleucine into protein, and that DHT 
restored levels of incorporation in elderly EDL muscles to levels seen in mature muscle 
fibres.  
The percentage increase in incorporation seen in the fast twitch EDL (fig 4.3A) fibres 
showed an impressive 72% increase in the elderly cohort, compared to only 17% 
increase for the control mature fibres.  The percentage increase resulting from DHT 
treatment was significantly greater for elderly fibres compared to mature muscle 
fibres, as seen with in AA transport in figures 4.2A-D. Slow muscle fibres (fig 4.3B) 
showed a less marked responses to DHT at increases of 15% in the elderly SOL cohort 
and only 0.1% in the mature SOL. This data correlates with the previous experiments 
measuring C14MeAIB and C14Isoleucine transport. This data offers evidence that DHT 
treatment can rescue the age-related deficits in both AA transport and subsequent 
protein synthesis, at least in the fast twitch EDL fibres.  
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Figure 4.3A.  Effect of DHT on incorporation of isoleucine into protein in fast and 
slow by muscle fibres ‘in vitro’. Fast twitch muscle fibre bundles were incubated in Ringer’s 
solution containing DHT and C14Isoleucine for 1hr, the fibre bundles were washed in PBS and 
snap frozen in liquid nitrogen, pulverised and lysed with NP40 buffer. The mixture was 
centrifuged and the supernatant was precipitated with TCA for scintillation counting to assess 
amino acid incorporation into protein. Mature mice were ~300 days old and elderly mice were 
over 700 days old. Only statistical difference was found in elderly controls (*) which were 
significantly reduced (p<0.05) compared to mature control, mature DHT and elderly DHT (all 
unmarked). 1-way ANOVA used, n=4.     
Figure 4.3B.  Comparison of effect of DHT on incorporation of isoleucine into protein 
in fast and slow by muscle fibres ‘in vitro’. Slow twitch muscle fibre bundles were 
incubated in Ringer’s solution containing DHT and C14Isoleucine for 1hr, the fibre bundles were 
washed in PBS and snap frozen in liquid nitrogen, pulverised and lysed with NP40 buffer. The 
mixture was centrifuged and the supernatant was precipitated with TCA for scintillation 
counting to assess amino acid incorporation into protein. Mature mice were ~300 days old and 
elderly mice were over 700 days old. There was a trend seen toward increase in elderly group 
(*), but DHT treatment did not result in statistically significant increases (p<0.05) in either the 
mature or elderly SOL. 1-way ANOVA used, n=4.  
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4.2.4 Effects of chloroquine on DHT-induced increases in amino acid transport by 
aged muscle. 
Taken together the results show that incubation of elderly fibres ‘in vitro’ with DHT is 
in some way able to increase levels of transporters extracted through our lysis method 
(Figures 4.1A-B) as well as increase activity of SNAT2 and LAT2 transporters and 
protein synthesis. This increase in activity brings the elderly EDL muscles to the same 
levels as mature muscle (Fig 4.2B, 4.2D, 4.3B). One possible explanation for these 
results is that DHT is able to change the cellular distribution of amino acid transporters 
so that they are more susceptible to extraction with mild detergent and have better 
access to extracellular amino acids.  One mechanism could involve movement of 
intracellular pool of transporters to the plasma membrane with consequent increased 
sensitivity to extraction by NP40.   
To test this hypothesis, experiments were repeated in the presence of chloroquine, a 
known blocker of vesicular recruitment (Chapman and Munro, 1994, Kashiwagi et al., 
2009).  The effects of chloroquine on SNAT2 activity assessed using C14MeAIB are 
shown in figures 4.4A-B. In these experiments the concentration of DHT was doubled 
over physiological levels to 4nM. A higher concentration of DHT was chosen because 
all animals used are at an age of ~300 days, which we have shown do not elicit a 
statistical upregulation at physiological doses of DHT.  
Chloroquine alone did not affect baseline amino acid transport.  As shown before, DHT 
increased uptake of C14MeAIB (p<0.05), and this increase was reversed by chloroquine 
in both fast and slow twitch muscle fibres. Chloroquine treated tissues showed no 
difference to baseline controls, suggesting that the accumulation of transporters as 
well as recycling back into storage compartments were blunted.  
Figure 4.4C-D show the same experiment for the uptake of C14Isoleucine to assess 
LAT2 activity. DHT increased the uptake of C14Isoleucine as expected and this was 
blocked by chloroquine in both fast and slow twitch muscle fibres.  As before, 
chloroquine abolished the DHT effect completely and chloroquine treatment alone 
was equal to the uptake seen with controls (p>0.05). A combination of CQ and DHT still 
blunted the DHT effect and was equal to baseline untreated control (p>0.05).   
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Figure 4.4A Effect of chloroquine on DHT induced elevation of C14MeAIB transport by 
EDL muscle fibres ‘in vitro’.  Fast twitch EDL muscle fibre bundles were incubated Ringer’s 
solution containing C14MeAIB for 1hr, in the presence or absence of chloroquine (CQ) and DHT 
as indicated. The fibre bundles were washed in PBS and snap frozen in liquid nitrogen, 
pulverised and lysed with NP40 buffer. The mixture was centrifuged and the supernatant was 
collected for scintillation counting to assess amino acid transport. Mature mice were used at 
~300 days old. Only DHT cohort (*) was found statistically different (p<0.05) to control, CQ, 
and DHT+CQ (unmarked). 1-way ANOVA used, n=3. 
 
Figure 4.4B Effect of chloroquine on DHT induced elevation of C14MeAIB transport by 
SOL muscle fibres ‘in vitro’.  Slow twitch SOL muscle fibre bundles were incubated Ringer’s 
solution containing C14MeAIB for 1hr, in the presence or absence of chloroquine (CQ) and DHT 
as indicated. The fibre bundles were washed in PBS and snap frozen in liquid nitrogen, 
pulverised and lysed with NP40 buffer. The mixture was centrifuged and the supernatant was 
collected for scintillation counting to assess amino acid transport. Mature mice were used at  
~300 days old. As before, only DHT cohort (*) was found statistically different (p<0.05) to 
control, CQ, and DHT+CQ (unmarked). 1-way ANOVA used, n=3.  
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igure 4.4A Effect of chloroquine on DHT induced elevation of C14Isoleucine transport 
by EDL muscle fibres ‘in vitro’.  Fast twitch EDL muscle fibre bundles were incubated 
Ringer’s solution containing C14Isoleucine for 1hr, in the presence or absence of chloroquine 
(CQ) and DHT as indicated. The fibre bundles were washed in PBS and snap frozen in liquid 
nitrogen, pulverised and lysed with NP40 buffer. The mixture was centrifuged and the 
supernatant was collected for scintillation counting to assess amino acid transport. Mature 
mice were used at  ~300 days old. Only DHT cohort (*) was found statistically different 
(p<0.05) to control, CQ, and DHT+CQ (unmarked). 1-way ANOVA used, n=3. 
Figure 4.4B Effect of chloroquine on DHT induced elevation of C14Isoleucine transport 
by SOL muscle fibres ‘in vitro’.  Slow twitch SOL muscle fibre bundles were incubated 
Ringer’s solution containing C14Isoleucine for 1hr, in the presence or absence of chloroquine 
(CQ) and DHT as indicated. The fibre bundles were washed in PBS and snap frozen in liquid 
nitrogen, pulverised and lysed with NP40 buffer. The mixture was centrifuged and the 
supernatant was collected for scintillation counting to assess amino acid transport. Mature 
mice were used at ~300. DHT cohort (*) was found statistically different (p<0.05) to control, 
CQ, and DHT+CQ (unmarked).  1-way ANOVA used, n=3.  
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4.2.5 Effects of low temperature on DHT-induced increases in amino acid transport 
by aged muscle. 
The transport of intracellular receptors can be blocked by lowered temperature. It has 
been previously shown that temperatures of  4°C block  membrane transport and 
pathways such as endocytosis are halted completely at this temperature(Wilson and 
King, 1986) The effects of incubation at 4°C on increased SNAT2 and LAT2 activity 
induced by DHT was compared to control conditions of 22°C. This was run over the 
course of 2hr instead of the usual 1hr. The ice-cold experiment would determine what 
portion of the increase in amino acid transport could be attributed to only SNAT2 and 
LAT2 transport as opposed to diffusion or any other unforeseen transport mechanism. 
Thus, this was done as an additional control to determine if the amino acid uptake 
observed was real.   
Figure 4.5 shows again that DHT increased uptake of MeAIB at 22°C in both fast and 
slow twitch muscle and that uptake of MeIAB was greatly reduced at 4°C.  In fact 
radioactive signals were barely above baseline when the experiment was carried out at 
4°C.  The bulk of amino acid transport seen in the assay could therefore be attributed 
mainly to active transport through SNAT2 and Lat2 rather than adsorption of 
radioactive amino acids to the tissue or any other form of transport into the tissue.   
Figure 4.5 Effect of low temperature on isoleucine transport by muscle fibres ‘in 
vitro’.  Fast and slow-twitch muscle fibre bundles were incubated Ringer’s solution containing 
C14Isoleucine for 2hr, and incubated with DHT, either at room temperature (220C) or 40C as 
indicated. The fibre bundles were washed in PBS and snap frozen in liquid nitrogen, pulverised 
and lysed with NP40 buffer. The mixture was centrifuged and the supernatant was collected 
for scintillation counting to assess amino acid transport. The white bars represent fast twitch 
EDL fibres and the black bars represent slow twitch soleus. 2-Way ANOVA used, n=3.  
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4.2.6 Effect of DHT on cellular location of SNAT2 in muscle fibres  
Elderly and mature tibialis anterior fibre bundles were incubated in Ringer’s solution in 
the absence and presence of 2nM DHT as indicted. The fibre bundles were snap frozen, 
sectioned and adsorbed onto slides for use in immunofluorescence microscopy. 
Figures 4.6B-C show mixed muscle (TA) from mature (~300 day old) mice.  Figures 
4.6D-E show mixed muscle from elderly (700 day old) mice.  Regions of interest are 
shown at higher magnification.   
Quantification of the data using pixel densitometry is show in figure 4.6A. Image J was 
used to quantify the signal at the plasma membrane and the data analysed. The 
densitometry confirms both the SNAT2 protein expression and C14MeAIB uptake data. 
Elderly TA fibres treated with DHT are statistically the same as mature control, 
suggesting reversal of SNAT2 dysfunction with DHT in the aged muscle.   
Figure 4.6A Effect of DHT on cellular location of SNAT2 in muscle fibres ‘in vitro’ 
densitometry quantification. Tibialis anterior muscle fibre bundles from 3 different mice 
were incubated for an hour in Ringer’s solution in the absence (Control) or presence of DHT. 
The fibre bundles were snap frozen, sectioned and adsorbed onto slides for 
immunofluorescence microscopy. The images were then quantified for magnitude of signal at 
the plasma membranes using ImageJ. Although a trend toward increase is seen, statistically 
there is no change in the mature groups response to DHT treatment (*) (p>0.05). Elderly DHT 
(unmarked) shows a significant increase (p<0.05) with DHT treatment from untreated elderly 
(+). Elderly DHT (unmarked) shows no difference to mature control group (unmarked) 
(p=0.137).  1-way ANOVA used, n=3.  
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Figure 4.6B Effect of DHT on cellular location of SNAT2 in mature muscle fibres ‘in 
vitro’.   Tibialis anterior muscle fibre bundles from mature (300 day old) mice were incubated 
for an hour in Ringer’s solution in the absence of DHT. The fibre bundles were snap frozen, 
sectioned and adsorbed onto slides for immunofluorescence microscopy.  Representative 
image.  
 
 
Figure 4.6C Effect of DHT on cellular location of SNAT2 in mature muscle fibres 
incubated with DHT ‘in vitro’.  Tibialis anterior muscle fibre bundles from mature (300 day 
old) mice were incubated for an hour in Ringer’s solution in the presence of 4nM DHT. The 
fibre bundles were snap frozen, sectioned and adsorbed onto slides for immunofluorescence 
microscopy. Representative image. 
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Figure 4.6D Effect of DHT on cellular location of SNAT2 in elderly skeletal muscle 
fibres ‘in vitro’.   Tibialis anterior muscle fibre bundles from elderly (+700 day old) mice were 
incubated for an hour in Ringer’s solution in the absence of DHT. The fibre bundles were snap 
frozen, sectioned and adsorbed onto slides for immunofluorescence microscopy. 
Representative image. 
 
 
 
Figure 4.6E Effect of DHT on cellular location of SNAT2 in elderly skeletal muscle 
fibres incubated with DHT ‘in vitro’.   Tibialis anterior muscle fibre bundles from elderly 
(+700 day old) mice were incubated for an hour in Ringer’s solution in the presence of 4nM 
DHT. The fibre bundles were snap frozen, sectioned and adsorbed onto slides for 
immunofluorescence microscopy. Representative image.
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4.2.7 Analysis of effects of DHT on C2C12 myoblasts and myotubes. 
The experiments to this point have analysed muscle fibres.  However, a typical muscle 
fibre is not homozygous in cell type throughout and the tissue lysates used in previous 
experiments consist of a mixture of both satellite progenitor cells, collagen, smooth 
muscle, plasma cells as well as fully formed muscle fibres. The aim of the next 
experiments was to see if the data observed in tissue could be replicated in the C2C12 
skeletal myoblast cell line. If successful, the cell line could be used for cell biology 
experiments based on exogenous gene expression and gene silencing to probe 
mechanisms further. 
C2C12 cells are similar in structure and function to commited skeletal myoblasts.These 
cells arise from the activation of satellite cells, which lie underneath the basal lamina 
of skeletal muscle and are triggered during injury (Le Grand and Rudnicki, 2007). As 
discussed before, these are critical for the regeneration and repair of skeletal muscle. 
The myoblast strain used here will serve to simulate the response of myoblasts alone 
to treatment with DHT.  Myoblasts incubated in MEM with 2% horse serum 
differentiate into myotubes. This is because of the different proportion of growth 
factors present in horse serum compared to normal growth media and the sudden 
reduction in the concentration of growth factors initiates the differentiation into 
myotubes (Lawson and Purslow, 2000).  Myotubes behave very much like mature 
myofibers, reacting to electrical stimuli with contraction although not as sustained and 
rapidly fatiguing. They serve as a model for the effects of DHT on skeletal muscle cells 
alone. Chloroquine has been extensively shown to inhibit vesicular trafficking 
(Puertollano and Alonso, 1999, Kashiwagi et al., 2009). CQ was used in the following 
experiments to test whether DHT was working through vesicle recruitment to increase 
SNAT2 and LAT2 transport. Flutamide (FLU) is a potent selective, competitive silent 
antagonist of the androgen receptor (Sarrabay et al., 2015). It was used to ascertain 
whether the DHT response is mediated through an AR element or through some other 
non-genomic receptor. Figures 4.7A-B show the effects of DHT, FLU, CQ, CQ + DHT and 
FLU + DHT on uptake of C14MeAIB (fig 4.7A) and C14Isoleucine (fig 4.7B). The same 
interventions are tested in myotubes shown in figures 4.7C-D on the uptake of 
C14MeAIB (fig 4.7C) and C14Isoleucine (fig 4.7D).  
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Figure 4.7A Effect of DHT, Flutamide and Chloroquine on C14MeAIB Uptake in 
myoblasts. Myoblasts were incubated in full media with C14MeAIB over one hour with 1 hr 
prior pre-incubation of antagonists (CQ and FLU) without radioisotope. Incubation and 
experiment ran at 37°C.  Cell wells washed in PBS and snap frozen in liquid nitrogen, pulverised 
and lysed with NP40 buffer. The mixture was centrifuged and the supernatant was collected 
for scintillation counting to assess amino acid transport. Only group showing significant 
difference (p<0.05) from control is DHT treatment alone(*). Chloroquine treatment group (CQ) 
shows no difference to DHT + Chloroquine (DCQ). Flutamide (FLU) also abolishes the DHT 
mediated increase in transport, showing no difference to control (CON) or DHT + flutamide 
(DFLU)(unmarked). 1-way ANOVA used, n=3.  
Figure 4.7B Effect of DHT, Flutamide and Chloroquine on C14Isoleucine Uptake in 
myoblasts. Myoblasts were incubated in full media with C14 Isoleucine over one hour with 1 
hr prior pre-incubation of antagonists (CQ and FLU) without radioisotope. Incubation and 
experiment ran at 37°C.  Cell wells washed in PBS and snap frozen in liquid nitrogen, pulverised 
and lysed with NP40 buffer. The mixture was centrifuged and the supernatant was collected 
for scintillation counting to assess amino acid transport. DHT treatment alone(*) showed 
significance (p<0.05) to all other groups (unmarked) except Flutamide (FLU, +)(p>0.05). 
Chloroquine treatment group (CQ) shows no difference to DHT + Chloroquine (DCQ)(p>0.05). 
Flutamide (FLU, +) shows no difference to any groups (p>0.05). 1-way ANOVA used, n=3.  
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Figure 4.7C Effect of DHT, Flutamide and Chloroquine on C14MeAIB Uptake in 
myoblasts. Myoblasts were incubated in full media with C14MeAIB over one hour with 1 hr 
prior pre-incubation of antagonists (CQ and FLU) without radioisotope. Incubation and 
experiment ran at 37°C.  Cell wells washed in PBS and snap frozen in liquid nitrogen, pulverised 
and lysed with NP40 buffer. The mixture was centrifuged and the supernatant was collected 
for scintillation counting to assess amino acid transport. DHT treatment alone (*) was 
significantly higher then all other groups( # and + p<0.05) . Chloroquine treatment group 
(CQ,#) shows no difference to DHT + Chloroquine (DCQ,#) nor control (#)(p>0.05). Flutamide 
(FLU +) also abolishes the DHT mediated increase in transport, showing reduction from # and * 
groups (p<0.05) but no difference to DHT+FLU (DFLU +)(p>0.05). 1-way ANOVA used, n=3.  
Figure 4.7D Effect of DHT, Flutamide and Chloroquine on C14Isoleucine Uptake in 
myotubes. Myotubes were incubated in full media with C14 Isoleucine over one hour with 1 hr 
prior pre-incubation of antagonists (CQ and FLU) without radioisotope. Incubation and 
experiment ran at 37°C.  Cell wells washed in PBS and snap frozen in liquid nitrogen, pulverised 
and lysed with NP40 buffer. The mixture was centrifuged and the supernatant was collected 
for scintillation counting to assess amino acid transport. DHT treatment alone(*) showed 
significance (p<0.05) to all other groups (unmarked). Chloroquine treatment group (CQ 
unmarked) shows no difference to DHT + Chloroquine (DCQ unmarked) nor control (CON 
unmarked) (p>0.05). Flutamide (FLU, unmarked) shows no difference to control (CON 
unmarked) (p>0.05). 1-way ANOVA used, n=3.
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4.2.8 Fluorescence imaging of SNAT2 and LAT2 localisation with DHT and Chlorquine 
treatment  
To assess the impact of CQ on SNAT2 localisation, TA muscle sections from mature 
mice were stained for SNAT2. Densitometry was used to compare the effects of no 
treatment to 4nM DHT, chloroquine and 4nM DHT + chloroquine. The densitometry 
quantification of the imaging results in figure 4.2A confirm the previous AA uptake and 
western blotting data. This serves as further evidence that DHT likely increases the 
quantity of functional SNAT2 transporters on the plasma membrane of skeletal muscle. 
Chloroquine inhibits vesicle trafficking and recruitment by increasing vesicular pH and 
directly abolishes the DHT effect (Puertollano and Alonso, 1999, Kashiwagi et al., 
2009). This effect can be seen by the absence of increased total plasma membrane 
signal of SNAT2 as compared to controls in 4.8B.  
 
 
4.8A Effect of DHT and CQ on cellular location of SNAT2 in muscle fibres ‘in vitro’ 
densitometry quantification Tibialis anterior muscle fibre bundles from 3 separate mature 
(300 day old) mice were incubated for an hour in Ringer’s solution in the presence of 4nM 
(supraphysiological) DHT or 40µM chloroquine. The fibre bundles were snap frozen, sectioned 
and adsorbed onto slides for immunofluorescence microscopy. DHT (*) group showed 
significantly higher plasma membrane fluorescence than all other groups (unmaked)(p<0.05). 
CQ treatment reduced signal to control levels (p>0.05). 1-way ANOVA used, n=3.   
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Figure 4.8B Fluorescence imaging of SNAT2 localisation in response to DHT and 
Chlorquine treatment Tibialis anterior muscle fibre bundles from mature (300 day old) mice 
were incubated for an hour in Ringer’s solution in the presence of 4nM (supraphysiological) 
DHT, 40µM chloroquine. The fibre bundles were snap frozen, sectioned and adsorbed onto 
slides for immunofluorescence microscopy. Representative image. 
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4.3 Discussion 
4.3.1 SNAT2 and LAT2 Protein Expression 
To determine the mechanism underlying the effects of DHT-treatment on amino acid 
transport in elderly mice, western blotting was used to investigate the expression of 
SNAT2 and LAT2 protein in fast-twitch and slow-twitch muscles isolated from young, 
middle aged and elderly mice.  As the results displayed in Figures 4.1A and 4.1B show, 
DHT treatment reversed the age-dependent decline in SNAT2 and LAT2 protein 
expression that was evident in our previous studies of the ageing effect on SNAT2 and 
LAT2 protein expression (Fig. 3.2A and 3.2B). With DHT treatment of 1 hr, we saw the 
protein expression of SNAT2 and LAT2 in elderly fast twitch muscle return to a level 
which was not different from that of the mature mice (p<0.05). Fast twitch fibres were 
rescued completely in this regard. While there was a trend toward the reversal of age 
related decline in SNAT2 and LAT2 in slow SOL, the difference was not statistically 
significant. This data suggests that an acute 1hr treatment with DHT has recovered 
functional SNAT2 and LAT2 levels in elderly fast muscle to that equal to much younger 
animals. While slow SOL also benefits from DHT treatment as we can see from the 
positive trends, the effect is not profound enough to reach statistical significance. It 
should however be noted that the slow SOL is more resistant to age related decline in 
the first place and experiences a lesser magnitude of dysfunction in ageing.  
In experiments of protein expression, young animals of around 100 days were tested 
as well as mature and elderly but ignored after the amino acid transporter protein 
expression studies. This is because the expression of both SNAT2 and LAT2 was found 
to be significantly reduced in comparison to their mature counterparts and 
inconsistent. Amino acid uptake was also shown to be impaired when compared to the 
mature (around 300 day old) counterparts. It was concluded that these mice were too 
young to use for the study of SNAT2 and LAT2 function. This is of course the opposite 
to what was initially expected. It is intuitive to think that the expression of these 
transporters would be at their highest during the developmental stages of an animal’s 
life, as this has been shown to be the time of the highest rate of growth. This is 
95 
 
 
attributed to greater nitrogen retention and increased protein synthesis rates (Davis et 
al., 1989, Davis and Fiorotto, 2009). However, our findings contradict this dogma.  
There are several plausible reasons for this result. It is known that testosterone 
concentrations in serum peak at around 15 weeks in mice, then decline in senescent 
animals (Banerjee et al., 2014). Banerjee et al. also shows that the expression of the 
transporter GLUT3 declines as mice get closer to the 100-day mark, then increases into 
maturity. It is possible a similar phenomenon is at work in SNAT2 and LAT2 expression. 
This could be due to these mice simply not having had sufficient time to produce large 
stores of the transporters in the intracellular pools when compared to fully mature 
mice. Thus, the limiting factor is likely to be the reserve pools of transporters available. 
It is also possible that there is a reduced response to the stimulation from anabolic 
steroids in immature mice stemming from a reduction in AR expression. In fact, it has 
been found that amino acids such as leucine and higher levels of insulin may act as the 
dominant anabolic triggers in very young animals rather than anabolic hormones 
(Suryawan and Davis, 2011). Whatever the underlying reason, more research needs to 
be completed to elucidate the role of SNAT2 and LAT2 in early development.  
4.3.2 AA uptake in tissue 
The results of the amino acid uptake studies mirror the increase in SNAT2 and LAT2 
expression. In elderly mice, DHT treatment on fast twitch skeletal tissue results in a 
significant increase (p<0.05) from untreated tissue. This is true in the uptake of both 
C14MeAIB and C14Isoleucine as seen in figures 4.2A-B and 4.2C-D. There is a trend 
towards greater uptake in both mature and elderly slow twitch muscle, but it does not 
show statistical significance (p>0.05). This data suggests that DHT rescues the age-
related decline in SNAT2 and LAT2 in fast twitch fibres.  
The increases in AA uptake correlates with the increases seen in the SNAT2 and LAT2 
protein expression data. The increase in both C14MeAIB and C14Isoleucine may be 
directly attributed to an increased amount of SNAT2 and LAT2 present at the plasma 
membrane. Mature mice did not see any significant benefit from 2nm physiological 
DHT treatment. This is likely because of the higher levels of testosterone and by proxy 
DHT in the mature cohort mice compared to the elderly (Banerjee et al., 2014). 
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The attenuated response seen in slow twitch muscle to DHT compared to the fast 
twitch remains to be fully elucidated. It is possible that the decreased response to 
anabolic stimuli in slow fibers is due to a reduction in AR expression, which has been 
documented in slow fibres (Hulmi et al., 2008). This finding also implies that the non-
genomic DHT effect might be AR mediated.  
The experiments using chloroquine were run using mature tissue to understand the 
physiological effect of these drugs in isolation. No elderly group was used. Tissues 
were pre-treated with chloroquine for 1hr prior to start of experiments to ensure 
vesicle alkylation (Ramm et al., 1994). DHT treatment was initiated at start of 
experiments for 1hr as before. Supra-physiological level of DHT was used (4nm) equal 
to roughly double that of physiological to assess the ability of CQ to blunt the DHT 
effect. 
As before, a significant (p<0.05) effect with DHT was noted. This effect was completely 
abolished in both chloroquine and chloroquine + DHT groups. This suggests that 
chloroquine is acting to prevent the recruitment of SNAT2 and LAT2 from storage 
vesicles. This effect of chloroquine has been observed in system A transporters (Hyde 
et al., 2002, Kashiwagi et al., 2009) as well as in GLUT4 trafficking as well (Romanek et 
al., 1993). This is due to the accumulation of chloroquine inside the storage vesicles 
and protonation, which results in a net alkylation of the entire vesicle (Chapman and 
Munro, 1994).  
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Table 4.1. Summary of DHT effects on Skeletal Tissue 
DHT 
Treatment 
MATURE FAST 
          
MATURE SLOW ELDERLY FAST ELDERLY SLOW 
SNAT2 Protein     •••    ••••    ••    ••• 
LAT2 Protein     ••••    ••••    ••••    ••• 
C14MeAIB 
Transport    •••    ••••    •••    •• 
C14Isoleucine 
Transport    ••    •••    ••    •• 
Protein 
Synthesis    ••    •••    ••    •• 
 
4.3.3 Fluorescence Imaging of SNAT2 localisation with ageing and DHT treatment   
The fluorescence imaging yielded results confirming the western blot and amino acid 
uptake data. There was a statistically higher membrane localised signal found in the 
DHT treated groups, as compared to their age equivalent controls. The magnitude of 
increase was also roughly consistent with what was found in the previous protein 
expression and amino acid uptake experiments. Clusters of fluorescence were 
observed either at the plasma membrane or surrounding the nuclei. This is consistent 
localisation studies involving GLUT4, which have shown that there is very little 
movement of actual vesicles in cytoplasm of cells but rather large accumulation 
around nuclei, and smaller storage sites along the plasma membrane (Lauritzen et al., 
2008). Intentional disruption of the trans-Golgi network has had no effect on uptake of 
amino acids, lending more credibility to the theory that in fact the second storage pool 
of amino acid transporters responsible for acute recruitment lies in close proximity to 
the plasma membrane (Hundal et al., 1994).  
4.3.4 AA uptake in C2C12 myoblasts and myotubes 
In preliminary experiments, we found varying expression levels of androgen receptor 
in myoblasts and myotubes, being significantly greater in myoblasts. In fact, myoblast 
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cells have been found to be the prime expressors of androgen receptors out of all cell 
types (Sinha-Hikim et al., 2004). In order to account for this potential confounding 
factor, uptake in both myoblasts and myotubes was measured independently.  
Myoblasts and myotube C2C12 cell lines were used for these experiments. Both our 
cell types have shown a significant increase (p<0.05) in the uptake of both C14MeAIB 
and C14Isoleucine in response to DHT (Fig 4.7A-B and 4.7C-D). Both of the antagonists 
were used to pretreat the tissues 1hr prior to commencement of experiments. This 
was a step that was not followed by Hamdi et al. in their tissue experiments, which 
showed an impartial abolishment of DHT effects with flutamide. It was essential to 
achieve complete blockade of the androgen receptor with flutamide and inhibition of 
vesicular recruitment and turnover with chloroquine. 
As before, C14MeAIB quantified SNAT2 transport, while C14Isoleucine quantified LAT2 
transport. Myoblast C14MeAIB uptake with 4nM DHT showed an increase of 45.91% + 
6.82% and increase of 39.8%  4.02% with C14Isoleucine uptake. These results were 
mirrored in myotubes, with and 38.12% 5.177 increase in C14MeAIB uptake and 49.67% 
 3.32% increase in C14Isoleucine.  
In all groups this DHT mediated increase in transport was abolished completely with 
chloroquine treatment. Chloroquine groups showed no statistical difference to 
controls. Combined DHT and chloroquine treatment group fared the same, an 
abolishment of the DHT was seen with not significant variance from controls. This 
supports the theory that DHT works to recruit SNAT2 and LAT2 from an internal 
vesicular pool. Once the movement of these stored transporters to the plasma 
membrane is inhibited by chloroquine, the acute effect of DHT treatment is completely 
abolished. This also shows that the recruitment of transporters is a rapid non-genomic 
process, being able to occur in under an hour. This is consistent with the rapid 
recruitment of the well-studied GLUT4 transporter (Becker et al., 2001). The 
equivalence in transport between control groups and chloroquine treated are 
consistent with the evidence that chloroquine disrupts all vesicular trafficking, both 
the recruitment of SNAT2 and its turnover (Michihara et al., 2005). 
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A similar blunting effect was seen in the flutamide treated groups. Flutamide is a 
selective competitive antagonist of the androgen receptor, which binds strongly to the 
receptor resulting in an inactive conformation that is unable to propagate a signalling 
cascade (Suh et al., 2015). Flutamide treatment completely abolished the DHT 
mediated increase in amino acid uptake in both the myoblasts and myotubes. 
Treatment with a combination of flutamide and DHT resulted in the same effect, the 
uptake was blunted back to baseline uptake not significantly different to controls 
(p>0.05). This was an interesting finding, as it suggests the action of DHT is likely 
mediated by an AR element.  
Previous data by Hamdi et al. has proposed that this mechanism is also mediated by 
the EGF receptor (Hamdi and Mutungi, 2010). However more recent evidence points 
to DHT working downstream of the EGFR. DHT is shown to greatly potentiate MAPK 
signalling, but only in the presence of baseline EGF binding (Lee et al., 2014). It is also 
possible that DHT is working as a co-activator of the EGFR, through an androgen 
receptor element.  More work is required to elucidate the exact mechanism of the 
acute action of DHT.  
4.3.5 Fluorescence imaging of SNAT2 localisation with DHT and Chloroquine 
treatment  
Our imaging results confirm the AA uptake and Western blotting data. DHT increases 
the quantity of functional SNAT2 transporters on the plasma membrane of skeletal 
muscle. We suggest that this fast (1hr) recruitment of functional transporters is 
obtained from plasma membrane proximal storage vesicles. Chloroquine inhibits 
vesicle trafficking and recruitment by increasing vesicular pH (Kashiwagi et al., 2009). 
This effect can be seen by the absence of increased total plasma membrane signal of 
SNAT2 as compared to controls.  
Interestingly, the chloroquine groups seem to show more pinpoint signals close to the 
membranes. This suggests that translocation of transporters into the plasma 
membrane proximal storage vesicles is still occurring, even in the presence of 
chloroquine. If this is accurate, it means that DHT is not only initiating the recruitment 
of transporters in plasma membrane localised vesicles but also the movement of any 
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transporters located in the Golgi into these vesicles. We do not see this effect in non 
CQ treatment groups, which gives more support to this theory.  
During the course of this chapter some limitations arose. Due to difficulty with 
fluorescence imaging of LAT2, only SNAT2 fluorescence data was obtained. This might 
have been a result of the relatively early availability of LAT2 antibodies and poor 
binding for use in the technique. Further work is necessary to assess LAT2 localisation 
in myoblast cells as a result of DHT and CQ treatment.  
Due to the scarcity of mice, the TA was chosen for use in sectioning and 
immunofluorescence. This made it impossible to assess fibre type differences between 
groups. See summary of limitations in section 6.7 for overview of all limitations.  
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Chapter 5 
5.1 Aim 
5.2 Results 
5.2.1  SNAT2 encoding plasmid transfection in C2C12 myoblasts 
5.2.2 Effects of DHT on SNAT2 transport in transfected and control C2C12 
myoblasts 
5.2.3 Effects of starvation on SNAT2 transport in transfected and control 
C2C12 myoblasts 
5.2.4 Effects of SNAT2 blockade on LAT2 transport in C2C12 myoblasts 
5.2.5 Effects of SNAT2 blockade with MeAIB on C14Isolecuine transport in 
C2C12 myoblasts  
5.2.6 Effects of Wartmannin, SP600125, and DHT on starvation induced 
increase in LAT2 transport in C2C12 myoblasts 
5.3 Discussion 
 5.3.1   SNAT2 Expression Vector 
5.3.2  Effect of SNAT2 blocking on LAT2  
5.3.3  Investigation of starvation induced LAT2 upregulation with JNK and                                                                          
.                          wortmannin      
5.3.4    Limitations 
5.1 Aim  
In this chapter, the focus lies on investigating the relationship between SNAT2 and 
LAT2. The aim is to gain more insight into the trafficking involved in the recruitment of 
these amino acid transporters. Specifically, the hypothesis that SNAT2 is a limiting 
factor determining LAT2 function. The focus is shifted to the study of modulating 
SNAT2 function rather than LAT2, because SNAT2 is a likely determining driver of LAT2 
transport. 
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5.2 Results 
5.2.1 SNAT2 encoding plasmid Transfection in C2C12 myoblasts 
C2C12 myoblasts were transfected with an expression vector coding for the SNAT2 
sequence. Cells were tested for SNAT2-GFRP using immunofluorescent imaging, 
determined by a strong luminescent signal in transfected cells. A positive fluorescent 
signal can be seen in figures 5.1C and 5.1D. Restrictive digest was also performed on 
expression vector and ran using agarose gel electrophoresis, which obtained a 
fragment of expected 1001 base pairs.  
C14MeAIB uptake experiments were run in order to test whether transfection would 
resort in greater SNAT2 mediated transport. A trend was found toward increase in 
C14MeAIB uptake with SNAT2 plasmid transfection as seen in figure 5.1E. This suggests 
that artificially creating a greater quantity of SNAT2 may have led to higher 
translocation to the membrane and thus more functional SNAT2. However, the 
difference between groups was not statistically significant. It is very likely that as with 
GLUT4, the recruitment of SNAT2 to the plasma membrane is limited at the uptake and 
release of transporter into and out of storage vesicles, which are the only route 
directly to the plasma membrane (Leto and Saltiel, 2012).  
As seen before in our imaging our transfection was successful. However, our 
transfection success rate was around 20% of total cells based on cell counts of 
fluorescent images (based on cell counts). This means that our uptake experiments 
using cell lysates were effectively an average of transfected and untransfected cells. 
While there was a trend seen towards higher uptake in the transfected group, the 
difference was not significant (p=0.1653). This shows that there likely only a small 
increase of functional SNAT2 at the plasma membrane as a result of the transfection at 
baseline conditions.  
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Figures 5.1A-D Fluoresence imaging of transfected and control untransfected C2C12 
myoblasts  5.1A- Control image at 509nm of untransfected C2C12 myoblasts. 5.1B- 
Corresponding brightfield image of 5.1A showing the same area. 5.1C-Representative image of 
C2C12 cells with SNAT2 plasmid in lipofectamine at 10x magnification at 509nm. 5.1C 
Representative image of C2C12 cells transfected with SNAT2 plasmid in lipofectamine at 40x 
magnification at 509nm.    
Graph 5.1E C14MeAIB Uptake in transfected and control untransfected C2C12 
myoblasts Bar graph of C14MeAIB uptake in control C2C12 cells and those transfected with 
SNAT2 expression vector. Increase is noted in cells transfected with SNAT2 plasmid, however 
this is not significant (p=0.1653). 1-way ANOVA used, n=3.  
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5.2.2 Effects of DHT on SNAT2 transport in transfected and control C2C12 myoblasts  
The next step in testing the transfection of C2C1 myoblasts with the SNAT2 vector was 
to assess the functional uptake of C14MeAIB through SNAT2 when treated with 4nm 
DHT. If the hypothesis of the SNAT2 plasmid increasing an intracellular pool of 
functional SNAT2 was correct then acute treatment should potentially recruit these to 
the plasma membrane leading to increased transport.   
The results in figure 5.2A validates this assumption and shows that with DHT 
stimulation the uptake of C14MeAIB was significantly increased (p<0.05) in the 
transfected cells compared to untransfected cells treated with the same concentration 
of DHT. This finding suggests that the transfection has increased the quantity of SNAT2 
available for recruitment, leading to a higher level of functional SNAT2 at the plasma 
membrane. This process, as before is facilitated by DHT treatment.  
Figure 5.2B shows that the magnitude of increase in the transfected cells was over 60% 
that of untransfected cells treated with same concentrations of DHT. Cells were 
cultured in full media as normal, and DHT was added at start of experimental run, 
which was run at 37°C in full media for 1hr. 
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Figure 5.2A Effect of DHT on C14MeAIB in transfected and untransfected C2C12 
myoblasts Bar graph showing effect of DHT treatment on transfected C2C12 cells, cultured in 
full media at 37°C, treated with 4nM DHT for 1hr in full media. White bars represent no DHT, 
black bars are DHT treated. Control and transfected do not show significant difference 
(p>0.05). DHT treated control (*) shows greater uptake to both control and transfected 
(unmarked)(p<0.05). DHT treated transfected (+). Transfected treated with DHT (+) show 
higher uptake than all other groups (p<0.05). 1-way ANOVA used, n=3. 
Figure 5.2B Extent of change with transfection alone compared to transfection and 
DHT C2C12 myoblasts cultured in full media at 37°C, treated with 4nM DHT for 1hr. Bar 
graph showing percentage change in C14MeAIB uptake represents effect of transfection in 
control (white) group and DHT treated (black) group. Baseline used are untransfected and 
untransfected DHT treated respectively. The magnitude of change is significantly greater 
(p<0.05) in transfected + DHT than in transfected alone. 1-way ANOVA used, n=3.
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5.2.3 Effects of starvation on SNAT2 transport in transfected and control C2C12 
myoblasts 
Experiments were repeated to assess the effects of starvation on SNAT2 recruitment. 
Starvation is a known up regulator of SNAT2 and works through a distinct pathway 
from DHT (Kashiwagi et al., 2009). Therefore, starvation treatment serves to show 
whether the overexpressed SNAT2 was fully functional and responsive to physiological 
triggers other than direct hormone stimulation.  
Figure 5.3A shows that starvation did increase the uptake of C14MeAIB in transfected 
C2C12 myoblasts when compared to untransfected cells (p<0.05). Figure 5.3B shows 
the magnitude of change. Cells were starved for 3hrs in HBSS prior to start of 
experiment, which was then incubated at 37°C in HBSS for 1hr. 
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Figure 5.3A Effect of starvation on C14MeAIB in transfected and untransfected C2C12 
myoblasts Bar graph showing effect of starvation on transfected C2C12 cells, cultured in full 
media at 37°C, pre-starved for 3hr in HBSS and incubated for 1hr in HBSS. As before, control  
and transfected do not show significant difference (unmarked) (p>0.05). Starved control (*) is 
different from all other groups (p<0.05). Transfected starved (+) is statistically higher than all 
groups ( p<0.05). 1-way ANOVA used, n=3. 
 
 
Figure 5.3B Extent of change with starvation alone compared to transfection and 
starvation C2C12 myoblasts cultured in full media at 37°C prestarved for 3hr in HBSS, then 
incubated for 1hr in HBSS. Bar graph showing percentage change of C14MeAIB uptake. White 
bar represents effect of transfaction alone, whilst black bar represents the effect of 
transfection between starved cells. Baseline are untransfected and untransfected starvation 
groups respectively. The magnitude of change is significantly greater (p<0.05) in transfected 
starvation (+)  then in transfection alone (unmarked). 1-way ANOVA used, n=3.
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5.2.4 Effects of SNAT2 plasmid transfection on C14Isoleucine transport in C2C12 
myoblasts 
As stated before, an assumption was made that SNAT2 activity is directly correlated to 
LAT2 transport. Therefore, effect of artificially upregulating SNAT2 transporter protein 
in C2C12 myoblasts on LAT2 transport was assessed by measuring C14Isoleucine 
transport in transfected C2C12 myoblasts. As figure 5.2A has shown a significant 
increase in C14MeAIB transport with DHT treatment, this experiment was performed to 
determine if an abundance of intracellular SNAT2 would likewise increase LAT2 
transport. As figure 5.4 shows, there is no statistically significant difference between 
the DHT response in untransfected cells when compared to those transfected with the 
SNAT2 plasmid. There is however a trend toward increased transport.  
 
 
Figure 5.4 Effect of SNAT2 plasmid transfection on C2C12 myoblasts treated with 
DHT. Bar graph showing C2C12 myoblast uptake of C14Isoleucine. Cells were transfected with 
plasmid coding for SNAT2. Myoblasts were cultured in full media at 37°C, and treated with 
4nM DHT for 1hr in full media for experimental runs. Control untransfected showed no 
difference to transfected (unmarked white) (p>0.05). DHT treated controls (DHT *) showed no 
difference to transfected DHT (TRAN + DHT *) (p>0.05). Both DHT treated showed significantly 
higher uptake than non DHT groups (p<0.05). 1-way ANOVA used, n=3.
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5.2.5 Effects of SNAT2 blockade with MeAIB on C14Isolecuine transport in C2C12 
myoblasts  
The above experiments suggested that artificially increasing SNAT2 protein content in 
C2C12 myoblasts did not lead to increases in LAT2 transport, even in the presence of 
DHT. The next step was to test whether the blocking of SNAT2 would in turn have a 
negative impact on LAT2 function. This was achieved by preincubating C2C12 
myoblasts in varying concentrations of MeAIB (non-radioactive). At high 
concentrations MeAIB blocks the SNAT2 transporter, a phenomenon known as trans 
inhibition (Kashiwagi et al., 2009).  
Figure 5.5A shows two concentrations of MeAIB used, 3.3mM and 5.0mM and the 
effect of this block on C14Isoleucine uptake in C2C12 cells in full media. All blocking 
groups were significantly lower than control (p<0.05) 3.3mM MeAIB resulted in 52.83% 
(±5.22%) reduction in blocking from control group, while maximal block was achieved 
with 5.0mM MeAIB at a reduction of 77.03% (±2.51%). MeAIB used at 5mM provided 
maximal reduction in LAT2 transport. In this instance MeAIB serves to block entry of 
small amino acids necessary to drive LAT2 (Hatanaka et al., 2001).  
Figure 5.5B illustrates the blunting of the magnitude of the starvation response in LAT2 
transport, a very large increase is noted in starved cells compared to unnstarved 
controls. Interestingly, MeAIB still acts to blunt this large increase by approximately 
half. Because the cells are in AA free media (HBSS) this effect cannot be attributed to 
prevention of AA uptake.  
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Figure 5.5A Effects of blocking concentrations of MeAIB on C14Isolecuine transport in 
C2C12 myoblasts in full media Bar graph showing effect of high concentration MeAIB on 
C2C12 cells, cultured in full media at 37°C. Cells were pre-treated with various concentrations of 
MeAIB for 1hr in full media, experiment was performed over the course of 1hr in full media in 
the presence of corresponding concentrations of MeAIB. Both 3.3nM and 5.0nM MeAIB were 
statistically lower (* and +, p<0.05) than control (unmarked). 1-way ANOVA used, n=3.  
 
Figure 5.5B Effects of blocking and normal concentrations of MeAIB on C14Isolecuine 
transport in C2C12 myoblasts under starvation Bar graph showing effect of blocking and 
non-blocking concentrations of MeAIB on C2C12 cells, cultured in full media at 37°C. Cells were 
pre starved for 3hrs in HBSS, pre-treated with various concentrations of MeAIB for 1hr in HBSS. 
Experiment was performed over the course of 1hr in HBSS in the presence of corresponding 
concentrations of MeAIB. Starvation control (black, unmarked) showed no difference to 0.5nM 
MeAIB (dotted, unmarked). Control unstarved cells (white, *) showed significantly lower 
uptake to all groups (p<0.05). Maximal blocking concentration of 10µM MeAIB (dashed, +) 
blunted the starvation effect (seen in starved and 0.5nM MeAIB) significantly  (p<0.05). 2-way 
ANOVA used, n=3.
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5.2.6 Effects of Wartmannin, SP600125, and DHT on starvation induced increase in 
LAT2 transport in C2C12 Myoblasts  
When comparing the starvation induced increase in transport between SNAT2 and 
LAT2, it was noted that LAT2 transport increased to a greater extent than SNAT2 
transport. As seen in figure 5.6A, there is a much greater effect seen in LAT2 transport 
then SNAT2 transport. (p<0.05) This quantified as a percentage from baseline (non- 
starved cohorts) equates to 1534.09% increase in LAT2 transport VS a 49.96% increase 
for SNAT2 transport. LAT2 transport is 30.62 times greater than SNAT2 transport under 
starvation conditions. 
Because these experiments were run in HBSS after 3hr of starvation, the question of 
where LAT2 is obtaining small amino acids to drive the exchange for C14Isoleucine 
arises. A hypothesis that SNAT2 and LAT2 act as transceptors and signal through the 
JNK pathway to initiate proteolysis in response to starvation was proposed.   
To test our hypothesis of SNAT2 signalling through the JNK pathway, we used the 
anthrapyrazolone selective JNK inhibitor SP600125 (Sigma Aldrich, UK). In these 
experiments, cells were pre-starved for three hours in HBSS before the 
commencement of uptake experiments as before. SP600125 was used at a 
concentration of 10nM which has maximal effect without significantly effecting any 
other physiological processes (Kashiwagi et al., 2009).  
Figure 5.6A Comparison of starvation induced upregulation of C14MeAIB and 
C14Isoleucine in C2C12 myoblasts Bar graph showing effect of starvation on transfected 
C2C12 cells, cultured in full media at 37°C, pre-starved for 3hr in HBSS and ran for 1hr in HBSS. 
SNAT2 signifies  C14MeAIB and LAT2 signifies C14Isoleucine. There is a significant difference 
(p<0.05) between the two groups, n=3.  
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Figure 5.6B Effects of Wartmannin and SP600125 on starvation induced increase in 
LAT2 transport. C2C12 myoblasts were cultured in full media at 37°C, pre starved for 3hr in 
HBSS alone and then incubated for 1hr in HBSS with or without drug treatments as indicated. 
Black bars represent control fed full media and white bars starvation in HBSS. Fig 26B is the 
same data isolated to show differences. DHT (*) shows no increase in comparison to control 
starved (p<0.05). Wartmannin shows 44.02% ±3.89% reduction compared to starvation control 
(p<0.05). Wartmanin (+) shows no difference to DHT+Warmanin (+)(p>0.05).  2-way ANOVA 
used, n=3. 
Figure 5.6C Effects of Wartmannin and SP600125 on starvation induced increase in 
LAT2 transport. Data from Figure 5.6B, 4 groups isolated to show differences more clearly. 
SP6000125 blunts the starvation induced upregulation completely, showing no difference to 
control (p>0.05). SP600125+DHT shows no difference to either control nor SP600125 alone 
(p>0.05). SP600125+Wartmanin suggest additive effect, showing reduced uptake to all groups 
tested (p<0.05) 2-way ANOVA used, n=3. 
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5.3 Discussion 
5.3.1 SNAT2 Expression Vector 
We developed a SNAT2 expression vector with the aims of artificially upregulating 
SNAT2 in C2C12 myoblasts. This made it possible to assess whether LAT2 transport was 
directly limited by the small amino acid gradient produced by SNAT2. It also tested the 
possibility of SNAT2 upregulation as a means of increasing LAT2 transport, leading to 
increased net protein synthesis. Studies with GLUT4 have shown that upregulating 
expression of the transporter do not lead to proportionally higher levels of active 
GLUT4 on the plasma membrane, because the amount of transporter available for 
recruitment in vesicular compartments is tightly controlled  (Brozinick et al., 1997). The 
aim of these experiments was to determine if this was also the case with SNAT2. 
The transfection of the plasmid was successful as evidenced by figures 5.1A-D. The 
results in figure 5.1E however shows no significant increase in C14MeAIB with 
transfection. This suggests that transfection alone likely does not translate to a 
significant upregulation of functional SNAT2 transporter on the plasma membrane. 
This is consistent with findings from studies on GLUT4, which show that extra 
cytoplasmic transporter levels do not correlate proportionally with increased 
concentrations of the transporter on the plasma membrane (Leto and Saltiel, 2012).  
However, as shown in our figures 5.2B and 5.3B the magnitude of response to both 
DHT and amino acid starvation is significantly higher in the transfected cells. This 
suggests that there is an increased capacity for SNAT2 recruitment, potentially 
stemming from increased packaging and availability of SNAT2 inside terminal storage 
vesicles proximal to the plasma membrane.  
As evidenced by the data in figure 5.4 there is no change on LAT2 transport in response 
to SNAT2 overexpression using an SNAT2 plasmid transfection in C2C12 cells. This 
holds true in both control C2C12 myoblasts as well as DHT treated groups. This was not 
surprising, as the increased expression of SNAT2 in transfected cells did not increase 
C14MeAIB transport. This provides more evidence that there was little increase in 
functional SNAT2 protein at the plasma membrane resulting from transfection alone.   
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This has also shown that total protein SNAT2 overexpression alone using a SNAT2 
plasmid in C2C12 myoblasts is likely not a feasible method for the direct upregulation 
of LAT2 activity. 
However, using DHT to upregulate LAT2 in transfected cells also did not lead to higher 
uptake of Isoleucine (fig 5.4). This suggests that increasing the small amino acid 
gradient over baseline does not lead to increased LAT2 activity. It is likely that small 
amino acid availability is not a rate limiting factor in LAT2 function and that increasing 
the substrate concentration is not a feasible way to induce LAT2 activity.  
5.3.2 Effect of SNAT2 blocking on LAT2  
When SNAT2 transport is significantly impaired, LAT2 activity suffers. This is evidenced 
by our blocking experiments using blocking concentrations of MeAIB as seen in figure 
5.5. When SNAT2 was completely blocked, the small neutral amino acid gradient was 
impaired, reducing LAT2 transport. It has been shown that blocking cells for prolonged 
periods of 5 days with saturable concentration of MeAIB results in significant depletion 
of branched chain amino acids such as leucine (Pinilla et al., 2011). However the 
connection to LAT2 has not been previously made in these findings. 
It is likely that under SNAT2 impairment LAT2 is unable to function at its normal 
capacity, due to the unavailability of small neutral amino acid substrates necessary for 
its normal function as an AA exchanger. It should be noted that even at full block of 
SNAT2, LAT2 still retained roughly 23% of activity as seen in figure 5.5. This may be due 
simply to incomplete depletion of small amino acids in the cell. This is further 
supported by the abundance of amino acids inside the skeletal muscle cell. Our chosen 
pre-blockade of 3 hours with MeAIB results in about 20% residual small neutral amino 
acid concentration without activating autophagy (Evans et al., 2008). Even without an 
external source of new small neutral amino acids, the cell is in a constant state of 
protein turnover, producing potential substrates for LAT2 (Bevington et al., 2002).  
We can conclude from our findings that SNAT2 is likely the main regulator of the small 
neutral amino acid gradient necessary for LAT2 function in conditions of nutrient 
scarcity, SNAT2 transport accounting for the great majority of the latter’s substrates.   
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This has possible implications for further research. LAT2 provides much of the 
necessary protein building blocks for fast dividing cancer cells, and its downregulation 
has shown to halt the pervasiveness of these cells (Janpipatkul et al., 2014). Instead of 
targeting LAT2 directly, it may be possible to partially blunt its function with the use of 
a compound that is relatively benign like MeAIB. This could be a feasible targeted 
therapy, as fast dividing cells rely on higher LAT2 function and have higher substrate 
requirements (Barollo et al., 2016).  
5.3.3 Starvation induced LAT2 upregulation and effects of JNK inhibition and 
wortmannin  
As noted in the previous section, saturable concentrations of MeAIB (>5nM) blunt the 
starvation induced LAT2 upregulation. This effect can be explained by a possible 
transceptor function of SNAT2. It has been shown that SNAT2 blockade using a 
saturable concentration of MeAIB results in decrease in the starvation induced 
upregulation of SNAT2 (Gazzola et al., 2001, Ling et al., 2001, Lopez-Fontanals et al., 
2003). It has also been proven that amino acid deprivation causes an activation of the 
JNK pathway, leading to both an increased transcription of amino acid transporters 
and proteolysis (Kashiwagi et al., 2009, Zhou et al., 2015a). Because of these findings, 
the role of JNK was studied further.  
Interestingly, starvation did not produce as a profound effect on SNAT2 function 
compared to LAT2. LAT2 uptake was 30.62 times greater under starvation conditions 
then SNAT2. This suggests that SNAT2 is not as sensitive to the JNK pathway, which has 
been found to be instrumental in starvation induced SNAT upregulation. (Kashiwagi et 
al., 2009) It is however possible that SNAT2 simply does not respond quickly enough 
through this pathway, requiring more time than our experimental runs allowed to 
achieve full transporter regulation.  
MeAIB itself does not inhibit the phosphorylation of JNK at concentration tested up to 
10mM (Hyde et al., 2007). However as Bracy et al. have shown, the use of MeAIB at 
saturable concentrations effectively locks the MeAIB substrate in an inward facing 
direction SNAT2, resulting in the phenomenon of trans-inhibition (Bracy et al., 1986). 
This likely produces an unstable confirmation of SNAT2 associated with no JNK 
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phosphorylation (Nardi et al., 2015). This is opposed to SNAT2 in purely starved 
conditions which takes a stable outward facing form that is able to activate the JNK 
pathway likely leading to increases in both its own recruitment from vesicular pools 
and increased transcription (Hyde et al., 2007). In other words, if there is amino acid 
flux through the transporter no starvation induced cascade effects are propagated by 
SNAT2. When amino acid availability dwindles and no amino acids are moving through 
the SNAT2 domain, the stable form of the transporter is preferred, which leads to JNK 
phosphorylation and initiation of autophagy most likely by dissociating bcl-2 from 
Beclin1 leading to the formation of Beclin1/PI3K complexes (Zhou et al., 2015a). Figure 
5.3.3 illustrates this process in more detail. In this way it is possible that SNAT2 acts to 
regulate its own activity with changing nutrient availability controls the small neutral 
amino acid gradient inside the cell.  
5.3.3 Illustration of JNK signalling in autophagy Starvation induced JNK signalling works 
through numerous different mechanisms, of which the fast non genomic involves formation of 
Beclin1/PI3K complexes. Illustration used from: (Zhou et al., 2015a). 
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It is plausible that starvation induced increase in AA transport are mediated primarily 
through JNK. In Figure 5.6B we see that under normal starvation conditions, transport 
of C14Isoleucine through LAT2 is significantly increased when compared to control fed 
conditions. The magnitude of this effect is so great that It was not possible to show 
these two data points on the same linear graph, having to isolate the lower reading 
groups on figure 5.6C. However, when the cells were treated with SP600125, there 
was no observable increase in uptake when compared to fed controls. In other words, 
the starvation effect was completely abolished back to baseline.  
On the other hand Wortmannin, a non-reversible PI3K inhibitor produced only a 
44.02% (±3.89%) reduction in the observed starvation effect. This was noted using a 
relatively high concentration of wortmannin at 200nM (IC50= 1nM) (Akinleye et al., 
2013) It has been shown that wortmannin at these concentrations does not interfere 
with JNK phosphorylation. This suggests that JNK mediated signalling is not acting 
solely through PI3K but potentially via another undefined mechanism, possibly 
downstream from PI3K (Xing et al., 2008). 
Another notable finding arising from the previous set of experiments was that the DHT 
effect is absent in starvation conditions. This is clearly illustrated in figure 5.6B and 
contrasts with experiments ran in full media, which show a significant increase in 
transport with DHT treatment. This data provides additional evidence for the 
hypothesis stating that DHT is working through an EGFR mediated mechanism (Hamdi 
and Mutungi, 2010). In the absence of EGF signal in our HBSS starvation media, it is 
likely that DHT is not sufficient to elicit the EGFR mediated response and induce SNAT2 
recruitment.  
5.3.4 Limitations  
During this chapter certain limitations arose. Due to the limited availability of the 
radioactive tracers C14MeAIB and C14Isoleucine, only a limited variety of antagonists 
were used. More work is also needed to assess the use of EGF agonists in starvation 
conditions to provide further evidence to the non-genomic acute pathway of AA 
transporter recruitment. See limitations section 2.14 for all experimental limitations.  
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6.1 Effects of ageing on mice skeletal muscle 
During these experiments, we have uncovered several potentially novel findings.  
The preliminary work in Chapter 3 has set out the groundwork for elucidating some of 
the mechanisms at play in age related muscle dysfunction. Our data suggests that 
there is a marked decline in mice skeletal muscle size and function with ageing. In the 
studies of the effects of ageing on skeletal muscle a significant decrease in most 
measured parameters have been shown: total muscle weight (fig 3.1A), muscle to total 
weight ratio (Fig 3.1B), SNAT2/LAT2 protein expression (figs 3.2A-B), AA transport 
levels (figs 3.3A-C), protein synthesis (figs 3.4A-B), and SNAT2 mRNA levels (figs 3.5A-B) 
in our elderly cohorts compared to mature mice.  
As expected, we found a significant decrease in total muscle weight in mice which only 
occurs in the elderly group, and not in young or mature (Fig 3.1A). Young and mature 
mice showed statistically similar muscle weights. Age related muscle dysfunction 
manifests as skeletal muscle atrophy and reduced mass, explaining the findings in our 
elderly cohort.  
The observed reduction in muscle mass to total body weight ratio (Fig 3.1B) was also 
predicted as this is a product of adipose tissue accumulation and hallmark of 
sarcopenic obesity. The ratio of muscle mass in comparison to total body weight is 
reduced in a linear fashion, with a steady decline shown between age groups. This 
suggests the accumulation of adipose tissue is a part of normal ageing in these 
animals, possibly partially attributed to the levels of anabolic hormones which also 
decline in a gradual fashion throughout life (Chen et al., 2015a). Levels of anabolic 
steroids are unlikely to be the sole reason behind this, as the difference in 
testosterone levels between the young and mature animals is negligible compared to 
the difference between mature and elderly cohorts. This suggests that another factor 
is at play, whether that be metabolic changes or perhaps a result of reduced physical 
activity of the mice with ageing. 
As fat tissue is abundant in aromatase, an increasing amount of testosterone is 
converted to oestrogen with greater obesity (Chan et al., 2014). The increase in 
adipose cell size seen in obese human patient drives a metabolic cycle that results in 
decreases in testosterone levels (Bekaert et al., 2015). It is possible that fat tissue   
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accumulation therefore is a self-perpetuating cycle in the mice cohorts, that occur 
throughout the lifespan only reaching a measurable detrimental effect on muscle 
function once an animal has reached a critical elderly age. It should be noted that only 
three age points were used in our experiments however, which limits extrapolation of 
these effects on the broader course of the mice lifespan (see experimental limitations 
2.14).  
It has been shown in Chapter 3 that age related muscle dysfunction affects some 
muscle types more than others. It is generally believed that ageing affects mainly type 
2 fibres while sparing type 1 fibres in humans  (Lexell et al., 1988, Balagopal et al., 
2001). This effect has been seen repeatedly in our experiments. The fast twitch fibres 
showed a greater reduction in both SNAT2 and LAT2 protein levels, AA transport and 
protein synthesis with ageing compared to their slow twitch counterparts. In other 
words, slow twitch muscle was more resistant to detrimental age induced changes.  
The mechanism underlying this observation remains unknown. It has been shown that 
fast twitch EDL mice skeletal muscle undergo much greater denervation compared to 
slow twitch SOL (Chai et al., 2011). The fibre transition observed by Chai et al. involved 
a trend toward the phenotype majority in a given muscle, in other words in slow SOL 
there was a fast to slow fibre type transition observed, while in fast muscle there was a 
slow to fast transition (Gannon et al., 2009). Considering that the fast twitch fibres are 
more prone to a loss in enervation and subsequent atrophy, it makes sense that our 
fast fibres show a greater overall decline in function when compared to slow muscle.   
It has been shown in chapter 3 (Figures 3.4A and 4.3A) that the rate of protein 
synthesis, regardless of age group, is consistently higher in slow-twitch predominant 
muscle as opposed to corresponding fast-twitch muscle. This finding is supported by 
techniques measuring in vivo muscle protein synthesis (Chen et al., 2015a). It has been 
shown that exercise upregulates the expression of AR density in both skeletal muscle 
fibre types, in this way modulating the local anabolic response to the same circulating 
testosterone levels and resulting in increased hypertrophy of the muscle  (Aizawa et 
al., 2011, Horii et al., 2016). It is plausible that in mice, the slow twitch SOL undergoes 
more frequent use, which leads to increased androgen receptor expression and thus   
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higher response to DHT.  It should also be noted that he results from Chapter 3 show 
that the drop in amino acid transport associated with ageing is relatively proportional 
to the decrease in protein synthesis, suggesting a deficiency in the synthesis of amino 
acids into proteins in aged muscle is unlikely.  
Protein synthesis declines with age in both fibre types. However, we have shown that 
the magnitude of decrease is lower in slow twitch fibres, which appear to be more 
resistant to ageing (3.4A-B). Although a number of studies have reported a loss in 
mixed muscle and myofibrillar proteins with age (Welle et al., 1993, Rooyackers et al., 
1996, Balagopal et al., 1997), these particular studies were performed on muscle 
biopsies derived from humans. As most muscles in the body consist of a mixture fast-
twitch and slow-twitch fibres, from these studies it is difficult to assess exactly which 
of these fibres are affected most by ageing.  
We can relate these findings to development of sarcopenic muscle dysfunction. The 
loss of fast twitch muscle has been shown in sarcopenia with the use of other 
analytical techniques (Deschenes et al., 2013). Consistent with our work, ageing has 
also been shown be Deschenes et al. to decrease the fractional synthetic rates of type 
2a and 2x myosin heavy chains in human muscle biopsies. Together, these findings 
suggest that sarcopenia may arise from the sum of an age-dependent fibre type shift 
and overall decline in muscle protein synthesis.  
As shown before in this thesis, the reduction in protein synthesis is coupled with a 
decline in both SNAT2 and LAT2 protein (Figs 3.4A-B). The effect on amino acid 
transporter protein levels directly mirrors the effects of overall transport in muscle 
fibre types. Like the decrease in protein synthesis with age, the decline in SNAT2 
expression was greater in the fast-twitch fibres than in the slow-twitch ones.  
When looking at SNAT2 expression on the mRNA level, a significant reduction has been 
found with ageing (3.5A-B). It would seem logical that this would translate to a lower 
response to DHT, however this was not seen. SNAT2 levels rise roughly proportionally 
to LAT2 levels with DHT treatment. This is likely because DHT, especially at 
physiological levels, does not initiate total recruitment of all available SNAT2 from 
internal storage pools. In other words, total SNAT2 reserve in the cell is higher than   
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can be additionally recruited with DHT treatment. It can be speculated that the 
decrease in protein synthesis and SNAT2 expression with age are linked and that they 
may be directly responsible for the development of sarcopenia.  
On the other hand, while it has been shown that the levels of LAT2 protein decline 
with age (3.5C-D), this reduction is seen independent of mRNA levels, which remain 
stable through the lifespan of the mice. Again, this does not seem to effect LAT2 
recruitment in response to DHT in elderly cohorts. We can speculate that as with 
SNAT2, physiological levels of DHT do not induce the total recruitment of LAT2 from 
intracellular pools. In fact, as seen in the pronounced response of LAT2 to starvation in 
mature mice, (Fig 5.3) there is a significant reserve of LAT2 in the cell.  
 
Table 6.1: Summary of Effects of Ageing on Mice Skeletal Muscle 
 
 
  
Baseline 
Ageing 
MATURE FAST 
          
MATURE 
SLOW 
ELDERLY FAST ELDERLY SLOW 
SNAT2 Protein     ••    ••••    •    ••• 
LAT2 Protein     ••••    ••••    •    •• 
SNAT2 mRNA    ••    ••••    •    •• 
LAT2 mRNA    •••    ••    •••    •• 
C14MeAIB 
Transport    •••    ••••    •    •• 
C14Isoleucine 
Transport    ••    •••    •    •• 
Protein 
Synthesis    ••    •••    •    •• 
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6.2 Effects of DHT treatment on ageing 
Total and free plasma testosterone reduces gradually with ageing in human subjects, 
leading to almost 50% of men defined as hypogonadal at the age of 80 (Stanworth and 
Jones, 2008). Ageing has the opposite effect on the plasma concentration of steroid 
hormone binding globulin which increase with age (Vermeulen et al., 1971). This 
severely curtails the levels of free testosterone in plasma and hence its bioavailability. 
Moreover, the decrease in plasma testosterone concentrations parallels the decline in 
skeletal muscle mass and function with age suggesting again that the reduced 
bioavailability of DHT may be one of the causes of sarcopenia.  
Our findings also show that treating small muscle fibre bundles, isolated from the 
elderly mice, with physiological concentrations of DHT rescues the age-dependent 
decline in amino acid transport in both muscle fibre types. However, the effects of DHT 
treatment, like those of age related decline on protein synthesis, were greater in the 
fast-twitch than in the slow-twitch fibres (Figs 4.3A-B). DHT treatment was also 
accompanied by an increase in the expression of SNAT2 and LAT2 expression in both 
fibre types (Figs 4.1A-B).  
Although the exact non- genomic mechanism involved was not investigated fully at 
present, we suggest that it involves the recruitment of SNAT2 from an intracellular 
compartment. The expression of SNAT2 is regulated by many factors including pH, 
amino acid deprivation growth factors and hormones (Hyde et al., 2002).  These 
factors have been shown to rapidly increase the function and expression of SNAT2, on 
the scale of minutes rather than hours (Hundal et al. 1994), providing further evidence 
for the storage compartment theory. It is also thought that these effects act 
independently from changes in transcription and translation rates, as these require a 
longer timescale then our 1hr experiments (Oliver et al., 2013). 
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Table 6.2: Summary of the Effects of DHT treatment on Elderly Mice Skeletal Muscle. 
 
 
 
 
 
 
 
 
DHT 
Treatment 
MATURE FAST 
          
MATURE SLOW ELDERLY FAST ELDERLY SLOW 
SNAT2 Protein     •••    ••••    ••    ••• 
LAT2 Protein     ••••    ••••    ••••    ••• 
C14MeAIB 
Transport    •••    ••••    •••    •• 
C14Isoleucine 
Transport    ••    •••    ••    •• 
Protein 
Synthesis    ••    •••    ••    •• 
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6.3 Study of SNAT2 and LAT2 recruitment 
The experimental data suggests that the stimulation of the recruitment of SNAT2 from 
an intracellular compartment by DHT is similar in manner to the effects of insulin on 
GLUT4 activation (Hyde et al., 2002). There are many parallels which can be drawn 
from the study of GLUT4 function. Because GLUT4 mechanisms are so extensively 
studied (Huang and Czech, 2007), study of this transporter system gives us a broader 
perspective as to which avenues to test to assess likely mechanisms involved. This, 
coupled with limited research in other system A transporters showing storage vesicle 
pool localisation and recruitment in response to insulin (Hyde et al., 2002) led to the 
initial hypothesis of SNAT2 and LAT2 recruitment from vesicle model.  
To test the theory of SNAT2 being held and utilised inside intracellular vesicles, 
chloroquine was used to inhibit vesicle movement to the cell membrane (figures 4.4A 
and 4.4B). The protein uptake studies were done as noted before using untreated 
mouse skeletal muscle tissue, myoblasts and myotubes. Groups were split into control, 
DHT treated, and Chloroquine and DHT plus chloroquine treated. Chloroquine 
completely blunted the DHT induced SNAT2 and LAT2 increase in AA transport (Figures 
4.4A and 4.4B). These results were confirmed in the Immunohistochemical image 
studies, (Figure 4.8B) showing increases in signal in DHT treated groups, and no 
difference to controls in chloroquine and DHT + chloroquine groups.  
The work on SNAT2 and LAT2 transporters in starvation conditions resulted in several 
interesting findings. We saw that with complete blockage of SNAT2 by MeAIB 
saturation in normal media conditions, LAT2 activity would drop to around 20% of 
normal transport. This is most likely due to the gradient of small neutral amino acids 
being disrupted by impaired transport of any usable substrate for LAT2. This suggests 
that LAT2 is dependent on SNAT2 to function at full capacity.  
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It also shows that targeting SNAT2 by blocking can artificially reduce LAT2 transport 
without initiating proteolysis and an autophagic response. This is an important finding, 
because LAT2 is a potential therapeutic target that is over expressed in numerous 
cancer cells (Fuchs and Bode, 2005, Nawashiro et al., 2006, Sakata et al., 2009). It also 
shows that SNAT2 is likely the predominant supplier of small neutral amino acids inside 
the mouse skeletal muscle cell.  
 
 
 
Figure 6.4 Proposed mechanism of SNAT2 and LAT2 recruitment form intracellular 
vesicle pools in response to DHT. EGF in needed for the acute non-genomic DHT response, 
as evidenced by its lack of efficacy under starvation conditions. EGFR signals through 
RAF/MEK/ERK1/2 causing ERK phosphorylation. pERK1/2 causes recruitment from vesicular 
pools as well as long term increase in transcription. Image produced with Adobe Flash.  
 
 
    SNAT2 internal pool 
LAT2 internal pool 
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6.4 SNAT2 plasmid transfection 
The upregulation of SNAT2 by means of plasmid transfection has also yielded 
interesting results. The studies in Chapter 5 have shown that with upregulation of 
SNAT2, no further transport over baseline was seen with LAT2 (figure 5.1E). Therefore, 
LAT2 function at baseline SNAT2 transport level is likely not limited by small neutral AA 
availability as there is likely more than sufficient reserve created by SNAT2 under 
control conditions. Increasing this cytoplasmic small neutral amino acid reserve by 
artificially increasing SNAT2 levels does not increase transport through LAT2 even with 
the use of DHT (figure 5.4). DHT treatment in transfected cells does elicit a heightened 
response through SNAT2 (Fig 5.2A) showing that the increase in reserve SNAT2 from 
transfection is being recruited to a greater extent. Starvation also induces an increased 
response in C14MeAIB transport (Fig5.3A).  
The work shows further evidence for an interaction between the EGFR and androgen 
receptor in skeletal muscle. This phenomenon has been shown to be true in prostate 
cells (Bonaccorsi et al., 2004). It has been shown that EGF in combination with DHT 
elicit a greater anabolic response than DHT alone (Mukherjee and Mayer, 2008). There 
is evidence that EGFR signalling is greatly potentiated by DHT, suggesting that DHT acts 
as a coactivator of EGFR (Bonaccorsi et al., 2004, Lee et al., 2016a). However, a 
baseline EGF level is necessary for this pathway to function and to maintain healthy 
muscle function. These findings explain why under starvation conditions in HBSS 
(devoid of EGF) DHT treatment even at a high level of 4nM does not elicit any 
additional response over untreated cells (figure 5.6B). 
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6.5 SNAT2 and LAT2 transceptor function 
There have been many recent advancements in the field of transceptor research in the 
recent years. This has been especially plentiful in the study of yeast cells, where 
numerous transcectors have been identified (Conrad et al., 2014). These transporters 
have been shown to be integral in cell signalling, namely in the mTOR pathway (Van 
Zeebroeck et al., 2014). 
Recently, an uncharactarised transported related to SNAT2 and member of the SLC38 
solute carrier family, SLC38A9 was the centre of research. An 11-pass transmembrane 
protein, SLC38A9 has been found to be involved in mTOR signalling through the Rag-
Ragulator complex in response to varying nutrient levels (Jung et al., 2015, Rebsamen 
and Superti-Furga, 2016). These findings provide support for the crucial role of these 
related transporters in regulating homeostasis.  
The studies with JNK inhibitor SP600125 have yielding promising results. As graphs 
5.6B and 5.6C show, JNK inhibition completely abolishes the starvation induced 
proteolytic mechanism that greatly upregulates LAT2 function. It is possible that this is 
because SNAT2 is locked into a non-signalling conformation (signified as SNAT2˄), this 
LAT2 induction is significantly attenuated. It is plausible that both SNAT2 and LAT2 
signal through JNK, which induces proteolysis inside the cell providing substrate for 
LAT2 (and to a much lesser degree SNAT2). The current research implicates the JNK 
pathway in SNAT2 signalling in response to starvation (Kashiwagi et al., 2009), however 
there is little research in elucidating LAT2 signalling at present.   
In the blocking experiments using saturable concentrations of MeAIB in full media (Fig 
5.5A), LAT2 transport was blocked approximately 80%. However, when this same 
experiment was used after starvation (Fig 5.5B) the result of MeAIB blocking was only 
an approximate 50% reduction in the starvation induced increase in C14Isoleucine. This 
provides evidence that under normal conditions (full media) reducing SNAT2 transport 
reduces LAT2 transport, whilst under starvation both SNAT2 and LAT2 are likely both 
inducing a proteolytic response through JNK signalling. This is why SNAT2 block only 
elicits a 50% reduction in starved conditions. Fig 6.5 Illustrates a normal starvation 
response, compared to MeAIB block in Fig 6.6.   
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Figure 6.5 SNAT2 and LAT2 response in starved conditions. Proposed mechanism for 
response of SNAT2 and LAT2 to starvation. Both trigger a JNK mediated response which 
initiates proteolysis resulting in intracellular AA increase and self-upregulation of both 
transporters.  Image created using Adobe Illustrator.  
 
Figure 6.6 MeAIB saturable block of SNAT2 in starvation conditions. Only a partial 
reduction in starvation induced upregulation is possible due to the remaining LAT2 transceptor 
signalling, initiating AA release and its own upregulation. Image created with Adobe Illustrator.  
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A novel nomenclature is proposed of identifying SNAT2 and LAT2 transporter 
confirmations in order to differentiate signalling from non-signalling conformations of 
the protein. SNAT2˅ denotes an outward facing protein conformation that is ready to 
accept substrate, while SNAT2˄ donates an inward locked conformation that is 
associated with AA saturation and does not initiate JNK signalling. There is evidence of 
this conformational change in the clear discrimination of SNAT2 between extracellular 
and intracellular AA concentrations (Hundal and Taylor, 2009). 
Once the substrates leave SNAT2 and enter the cytoplasm, the conformation is 
returned to SNAT˅ state. When using MeAIB in saturable conditions, there is a 
sufficient quantity of MeAIB inside the cell to prevent the MeAIB substrate from 
entering the cell, it being kinetically more stable at the transporter site (Nardi et al., 
2015).  
It is proposed here that the stable SNAT˅ conformation is associated in JNK 
transmission and initiation of proteolysis. Under normal starvation conditions, the 
SNAT2 transport is found predominantly in this state due to lack of substrate needed 
for conformational shift. Under MeAIB saturation, the transporter finds itself locked 
into the unstable SNAT˅ conformation, which cannot initiate JNK transmission and 
downstream proteolysis. In this way MeAIB saturation blunts the amino acid 
deprivation response.  
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Figure 6.7 SNAT2 transceptor function Proposed two configuration states of SNAT2. SNAT˅ 
protein configuration accepts one sodium ion and one small amino acid. The gradient of 
sodium pushes the sodium molecule further into the complex, causing a conformational 
change to SNAT˄. SNAT˅ is the predominant “stable” conformation under starvation conditions 
and potentially facilitates JNK signalling. A saturation of MeAIB results in a more preferable 
SNAT˄ conformation due to the reduced dissociation of MeAIB from the active site, resulting in 
no JNK signalling.  
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6.6 Significant findings 
1. Elderly CD-1 mice exhibit a marked reduction in EDL and soleus muscle weight 
compared to young and mature mice. They also show a linear increase in total 
body weight to EDL and SOL weight ratio. 
2. SNAT2 and LAT2 protein levels are markedly reduced in elderly CD-1 mice as 
compared to mature mice.   
3. Transport of C14MeAIB, C14Isoleucine, and protein incorporation is reduced in 
elderly CD-1 mice compared to mature mice. The extent of reduction is greater 
in fast twitch EDL than in slow twitch soleus. Slow twitch muscles are more 
resistant to age related amino acid transport dysfunction.  
4. mRNA expression of SNAT2 is reduced in elderly CD-1 mice compared to 
controls but LAT2 mRNA levels remains statistically the same with age. 
5. DHT treatment increases C14MeAIB and C14Isoleucine transport into cells. It also 
increases SNAT2 and LAT2 protein level.  
6. Both Chloroquine and Flutamide treatment completely blunt the DHT effect. 
This suggests that SNAT2/LAT2 are recruited from an intracellular pool and that 
an AR element is required for DHT signalling.   
7. Under starvation conditions, LAT2 exhibits a much greater increase in transport 
than SNAT2.  
8. SNAT2 saturable block with MeAIB results in 77% reduction of baseline 
transport in LAT2. This suggests baseline SNAT2 transport is chiefly necessary to 
supply small amino acid gradient to drive LAT2.  
9. SNAT2 upregulation using expression vector has no effect on LAT2 function. 
This shows that increasing the SNAT2 reserve pool does not proportionally 
increase LAT2 transport and is likely not a limiting step.  
10. SNAT2˄, SNAT2˅, LAT2˄, and LAT2˅ nomenclature proposed to identify stable 
signalling conformations of these transporters, and unstable extracellular 
binding conformations.  
11. Data suggests that it is possible that SNAT2 and LAT2 signal through JNK to 
initiate proteolysis which mainly drives LAT2 transport under starvation 
conditions. 
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6.7 Further Work 
As in all fields of science, with answers often come more questions. There are many 
exciting developments under way in the field of muscle ageing. The best way forward 
is to study individual pathways in further detail to understand the role anabolics such 
as DHT play in concert with other biological processes on the broader scope of 
organism ageing.   
With further studies, it would be possible to better understand the mechanism DHT is 
using to activate the movement of vesicles containing SNAT2 and LAT2 to the cellular 
membrane. Live cell imaging can be used to study the internal localisation of SNAT2 
and LAT2 in response to stimuli. During the course of this work, LAT2 was found to be 
very difficult to image successfully (see experimental limitations 2.14). Therefore, 
better antibodies and imaging techniques are needed to quantify LAT2 localisation 
accurately.  
The transceptor action of SNAT2 and LAT2 need to be further elucidated. Specifically, 
to understand by what means SNAT2 is initiating proteolysis. This could be done using 
more specific inhibitors of different steps of the JNK and PI3K cascade. It is also likely 
that LAT2 serves a similar transceptor function. Molecular modelling of this receptor 
has identified possible interaction domains between PKA and PKB (Pochini et al., 
2014).  These potential binding sites need further research, and the means in which 
LAT2 is capable of signalling needs to be elucidated.  
Inhibition of specific pathways in JNK/ PI3K pathway would enable us to elucidate the 
phosphorylation cascades at work. As stated before, it is suggested that DHT is 
signalling through the EGFR and MAPK/ERK pathway to initiate recruitment of amino 
acid transporters. The exact nature of DHT binding to initiate this pathway is still not 
known. Molecular modelling of the EGF receptor complete with identification of an 
androgen responsive element or evidence of direct AR interaction would prove the 
theory that DHT is acting as a coactivator of the EGFR. Specifically, we require more 
evidence that DHT is working as a co activator of EGFR receptor, which in conjunction 
with a baseline signal leads to increased phosphorylation in the ERK1/ERK2 cascade.   
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Although experiments using inhibitors are useful, molecular imaging would give a 
clearer and more definite picture of what is happening.  
One recurrent problem in these studies was the poor binding of our LAT2 antibodies to 
the LAT2 transporter. This led to long incubation times due to very low initial signals. It 
is not surprising that more robust antibodies are not available, as LAT2 has only been 
identified relatively recently. Therefore, the creation of improved LAT2 antibodies 
would aid in the quantification of this important amino acid transporter. Better 
antibodies would allow for running live cell studies with adequate precision. Naturally 
as current antibodies are refined, better examples should be available.  
These experiments have studied only the acute, non-genomic pathway of DHT induced 
AA transporter recruitment. Therefore, further work is necessary in running in vivo 
DHT treatment in mice. This would be a better assessment of the suitability of DHT as a 
long-term treatment of sarcopenic muscle dysfunction in elderly mice. The most 
efficient way of doing this would be using sub dermal injections of a DHT impregnated 
pellet (McCullough et al., 2012, Okabe et al., 2013). This would eliminate the need for 
frequent injections and limit the stress caused to the animals. By exposing the animals 
to DHT for long durations, we could assess the effects not only of recruitment, but also 
of mRNA expression, total reserve protein, and AR expression. This would also 
elucidate any negative feedback and sensitisation issues surrounding chronic DHT 
treatment. Rudimentary safety profile of such treatment could also be assessed.  
In an in vivo model, it would also be possible to treat the animals using MeAIB in the 
aim to stop cell proliferation and prevent or reverse the growth of tumors. Very little 
research has been done in this regard. One group showing MeAIB inhibiting liver 
collagen formation after injury, showed that MeAIB halts the cell cycle by limiting 
nutrient availability (Freeman et al., 2004). The use of MeAIB did not show any overt 
toxicity in this study. Because LAT2 is increasingly found to be upregulated in tumours 
(Barollo et al., 2016), MeAIB could be used to artificially lower transport through LAT2 
by reducing the amount of small neutral amino acids available for co transport of 
branched chain AAs. In this way MeAIB could be used to control both AA type levels in 
the cell, without initiating proteolysis as SNAT2 would possibly remain in the unstable   
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SNAT2˄ confirmation, which is not conductive to pro proteolytic signalling. This could 
be of great therapeutic benefit in the treatment of malignancy and needs further 
study.  
The breakdown or recycling of both SNAT2 and LAT2 also require further study. To do 
this, one would need to look at levels of post translational modifications such as 
ubiquitination on SNAT2 and LAT2.  Recent studies have suggested that mTOR might 
have an action on ubiquitination of SNAT, which in turn reduces its recruitment (Chen 
et al., 2015b). It is necessary to assess the extent of the role these ubiquitination steps 
serve in overall transporter function.  
There is also scope to study the effect of DHT on satellite cell number in greater detail. 
It has long been believed that satellite cell reserve decreases with age. It is known from 
animal and human studies, that satellite cell density is heavily dependent on the fibre 
type (Mackey et al., 2014). It is also excepted that ageing causes a transition from fast 
twitch fibres to a slow phenotype (Neunhauserer et al., 2011). The relationship 
between these two factors needs further clarification. It is possible that the fibre type 
transition is a compensatory response to loss in satellite cell reserve.  
More work is required on assessing the extent of 5αReductase expression in different 
fibre types. Preliminary work shows that the cause of resistance to ageing we have 
seen in slow muscle fibres is likely related to increased expression of 5αReductase in 
this tissue. This means of course, that more testosterone is converted to DHT, exerting 
a greater anabolic response. However, from our experience the quantities of 5α-
Reductase present are so small that a more sensitive quantification methods are 
needed in the study of skeletal muscle.  
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